2025 台北醫學會研討會議程(2025-07-24暫定版)

地點：誠樸廳, 胡水旺國際會議廳、教學大樓一樓2101~2104教室、2203教室

時間：9/6(六) 8:30-17:30

時間	時程	議程						
8:30	30 min	**報到: 醫綜大樓外側一樓報到**						
9:00-10:45	105 min (25min *3)	**地點: 後棟16樓胡水旺國際會議廳** Opening Remarks (15min) **吳麥斯教授(臺北醫學大學校長)、施俊明教授(臺北醫學大學附設醫院院長)**						
		Plenary lecture	**Topic1- Future Diagnosis -精準醫學(Precision medicine)** **龔行健院士 (中央研究院院士, 國家衛生研究院榮譽研究員, 臺北醫學大學講座教授)**					
			Topic2- Future Treatment - 最新醫療發展 **Prof. Ryuichi Morishita (Endowed Chair Professor, Department of Clinical Gene Therapy, and Chief, Section of Gene Therapy, Department of Geriatric Medicine, Osaka University Medical School, Japan)**					
			Topic3- Future Hospital-人工智慧AI/綠能 **戴建丞博士 (經濟部產業技術司簡任技正)**					
10:45-11:00	15 min	Coffee Break I						
		後棟,胡水旺	前棟,誠樸廳	教學,2101 室	教學,2102 室	教學,2103 室	教學,2104 室	教學,2203教室
11:00-12:35	95 min	**Main Session**						
		Future Medical Education **未來醫學教育** **(附設醫院教學部)**	**潛龍之用：龍年世代對精準醫學的貢獻** **(附設醫院精準醫學研究中心)**	**兒童手術-從微創到機器人** **(附設醫院小兒外科)**	**醫療創新與AI應用** **(附設醫院事業發展部/創新前瞻中心)**	**智慧醫療 品質到價值** **(附設醫院醫品部)**	**腎絲球腎炎研討** **(附設醫院腎臟內科)** **(台灣腎臟醫學會合辦)**	

		Chairperson 吳明賢教授 (台灣大學醫學院特聘教授暨院長/台大附設醫院消化科醫師/台灣消化系醫學會理事長/台灣內科醫學會秘書長/台灣醫學會理事)	**Chairperson** 呂隆昇副教授 (臺北醫學大學醫學院副教授/附設醫院癌症卓越研究中心副主任)	**Chairperson** 黃富煥主任 (臺北醫學大學附設醫院外科部副主任暨小兒外科主任) 魏晉弘副教授 (臺北醫學大學醫學系副教授/衛生福利部雙和醫院小兒外科主任)	**Chairperson** 吳孟晃副教授 (臺北醫學大學醫學院副教授/附設醫院骨科部主任暨創新前瞻中心主任) 周百謙副教授 (臺北醫學大學醫學院副教授/附設醫院事業發展部主任)	**Chairperson** 蕭淑代副院長 (臺北醫學大學附設醫院副院長/中華民國護理師護士公會全國聯合會常務理事/台北市護理師護士公會理事長)	**Chairperson** 吳麥斯教授 (臺北醫學大學內科教授暨校長/雙和醫院腎臟內科主治醫師/台灣腎臟醫學會理事長) 許永和教授 (臺北醫學大學內科教授/台北市立萬芳醫院副院長及腎臟內科主治醫師)	
		Opening remark(5') 吳明賢教授 (台灣大學醫學院特聘教授暨院長/台大附設醫院消化科醫師/台灣消化系醫學會理事長) **Lecture 1 (30')** **Prof. Kimberly Lomis** **(Vice President for Medical Education Innovation, American Medical Association, USA)** **Data-Driven Transformation in Medical Education: Global Trends and AMA's Vision for the Future** **Lecture 2 (15')** 陳正文副教授 (輔仁大學醫學院醫學系副教授/耕莘醫院行政副院長/台灣ENT醫學會CBME教育主任委員) **From Concept to System: CBME Implementation Strategies and Outcome Assessment Framework**	**Opening remark(5')** 陶秘華研究員 (中央研究院生物醫學科學研究所研究員/生醫轉譯研究中心轉譯醫學專題中心執行長) **Lecture 1 (20')** 邵于宣教授 (台北醫學大學健康數據研究中心主任) **Lecture2 (20')** 莊士賢技術長 (嘉正生技技術長) **Lecture 3 (20')** 連加恩醫師/董事長 (宏碁智醫董事長) **Panel Discussion (30')** 呂隆昇副教授 (臺北醫學大學醫學院副教授/附設醫院癌症卓越研究中心副主任)	**Opening remark(5')** 黃富煥主任 (臺北醫學大學附設醫院外科部副主任暨小兒外科主任) **Lecture 1 (25')** **Dr. Tran Ngoc Son** **(Deputy Director of Saint Paul General Hospital in Hanoi, Vietnam)** **My Journey of MIS in Pediatric Biliary Diseases** **Lecture 2 (25')** 傅玉瑋醫師 (彰化基督教醫院兒童外科主任) **Evolution of MIS for Biliary Diseases: Taiwan Experience** **Lecture 3 (25')** 洪琬婷醫師 (台灣大學醫學院外科臨床助理教授/附設醫院外科部小兒外科主治醫師) **MIS for Choledochal Cyst in National Taiwan**	**Opening remark(5')** 曾俊儒教授 (臺北科技大學工業設計系教授/台灣醫學設計學會創會理事長) **Lecture 1 (25')** 楊為植先生 (創新工業技術移轉股份有限公司(ITIC)/顧問公司「核心觀點」(Presentality)的共同創辦人) 掌握人心的簡報藝術 **Lecture2 (25')** 張可佳技術長 (星創智慧科技技術長) 生成式AI：增進職場效率好幫手 **Lecture 3 (25')** 林昭陽執行副總 (威剛科技股份有限公司執行副總) **Implementation Cases of AMR and Physical AI in Healthcare Applications** **Panel Discussion (15')**	**Opening remark(5')** 蕭淑代副院長 (臺北醫學大學附設醫院副院長/中華民國護理師護士公會全國聯合會常務理事/台北市護理師護士公會理事長) **Lecture 1 (30')** 陳志維副主任 (臺北醫學大學附設醫院心臟內科主治醫師暨健康管理中心副主任) 運用智慧醫療工具改善心臟疾病病人照護結果 **Rethinking Innovation in Healthcare: Truths, Challenges, and Game Changers** **Lecture 2 (30')** 譚慶鼎教授 (國立臺灣大學醫學院耳鼻喉科教授/附設醫院新竹臺大分院副院長/耳鼻喉部主治醫師) 醫院智慧醫療規劃與提升品質與病安的影響 **Lecture 3 (30')**	**Opening remark(5')** 吳麥斯教授 (臺北醫學大學內科教授暨校長/雙和醫院腎臟內科主治醫師/台灣腎臟醫學會理事長) **Lecture 1 (25')** 吳逸文副教授 (臺北醫學大學附設醫院醫學系副教授/附設醫院研究部主任/腎臟內科主任) **Update on IgA nephropathy management: insight from KDIGO 2025 guideline** **Lecture 2 (25')** 黃道民醫師 (臺大醫院內科部腎臟科主治醫師/台灣腎臟醫學會腎病登錄委員會副主委) **Insights from the Taiwan Renal Biopsy Registry: Observational Findings**	

		in the Taiwan Society of Otorhinolaryngology–Head and Neck Surgery Lecture 3 (15') 陳建宇教授 (臺北醫學大學醫學系醫學教育暨人文學科教授/臺北醫學大學副教務長/附設醫院麻醉科主治醫師) 在地實踐的挑戰與創新：教學現場如何落實 CBME 與數據學習 Panel Discussion (15') Prof. Kimberly Lomis 陳正文副教授 陳建宇教授		University Children Hospital Panel Discussion (15') 魏晉弘副教授 (臺北醫學大學醫學系副教授/衛生福利部雙和醫院小兒外科主任)	吳孟晃副教授 (臺北醫學大學醫學院副教授/附設醫院骨科部主任暨創新前瞻中心主任) 周百謙副教授 (臺北醫學大學醫學院副教授/附設醫院事業發展部主任)	Assist Prof. GAO Yujia (Adjunct Assistant Professor and Director of Undergraduate Medical Education, Department of Surgery, Yong Loo Lin School of Medicine, NUS; Principal Investigator, iHealthTech, NUS, Singapore)	on Immunoglobulin A Nephropathy Lecture 3 (25') 高治圻副教授 (臺北醫學大學內科副教授/附設醫院內科部副主任) Novel biomarkers of IgA Nephropathy Panel Discussion & Closing (15') 洪冠予教授 (臺北醫學大學教授暨副校長/衛生福利部雙和醫院腎臟內科主治醫師)	
12:35-12:45	10 min	Lunch Break I						
12:45-13:45	60 min	Lunch Symposium						
		Special Symposium1 從不預期的死到有意義的生~安寧緩和醫療與器官捐贈移植 (附設醫院研究部/器官勸募暨移植中心) (學會邀請中)	Lunch Symposium1 (台灣百靈佳殷格翰股份有限公司)	Lunch Symposium2 (賽諾菲股份有限公司)	Lunch Symposium3 (台灣安進藥品有限公司)	Special Symposium2 外泌體的臨床應用發展 (附設醫院心血管研究中心) (中華民國血脂動脈硬化學會及財團法人心臟醫學研究發展基金會協辦)		
		Chairperson 李明哲教授 (臺北醫學大學醫學系教授/衛生福利部雙和醫院院長/財團法人器官捐贈移植登錄及病人自主推廣中心董事長) 江仰仁副教授 (臺北醫學大學附設醫院泌尿科主治醫師暨器官勸募	Chairperson 施俊明教授 (臺北醫學大學醫學院教授/附設醫院院長) 黃群耀教授 (臺北醫學大學醫學院教授/附設醫院副院長/台灣心肌梗塞學會理事長) Opening remark(5')	Chairperson 林幸榮教授 (臺北醫學大學醫學院講座教授/財團法人心臟醫學研究發展基金會董事長)	Chairperson 劉如濟教授 (臺北醫學大學醫學系教授/衛生福利部雙和醫院副院長/心臟內科主治醫師) Opening remark(5') 劉如濟教授 (臺北醫學大學醫學系教授/衛生福利部雙和醫院副院長/心臟內科主治醫師/台灣心肌	Chairperson 劉秉彥教授 (成功大學臨床醫學研究所教授/成大醫院內科部部主任/中華民國血脂動脈硬化學會理事長) 周德盈教授 (臺北醫學大學醫學院教授及精準健康中心主任/台灣個人化醫學研究學會理事		

		暨移植中心主任/長庚大學兼任副教授/社團法人中華民國器官捐贈協會理事長) **Opening remark(5')** 李明哲教授 (臺北醫學大學醫學系教授/衛生福利部雙和醫院院長/財團法人器官捐贈移植登錄及病人自主推廣中心董事長) **Lecture 1 (20')** 蔡宏斌主任 (臺北市立聯合醫院中興院區整合醫學照護科主任/財團法人器官捐贈移植登錄及病人自主推廣中心執行長) **Lecture 2 (20')** 鍾孟軒醫師 (臺北榮民總醫院外傷醫學科主治醫師) **Panel Discussion & Closing (15')** 江仰仁副教授 (臺北醫學大學附設醫院泌尿科主治醫師暨器官勸募暨移植中心主任/長庚大學兼任副教授/社團法人中華民國器官捐贈協會理事長)	施俊明教授 (臺北醫學大學醫學院教授/附設醫院院長) **Lecture 1 (25')** 徐千彝副教授 (臺北醫學大學醫學院副教授/附設醫院心臟內科主治醫師暨研究部副主任) **Comprehensive Protection for Heart Failure Patients Across LVEF Spectrum with Jardiance** **Lecture 2 (25')** 吳忠擇副教授 (臺北醫學大學醫學系副教授/衛生福利部雙和醫院新陳代謝科主任) **Empower with Empagliflozin: Unlocking the Superpower in CRM Management** **Panel Discussion & Closing (5')** 黃群耀教授 (臺北醫學大學醫學院教授/附設醫院副院長/台灣心肌梗塞學會理事長)		梗塞學會理事) **Lecture (45')** 王宇澄副教授 (亞洲大學醫學暨健康學院副教授/亞大醫院內科部兼心臟內科主任) **The Crucial Role of Timely LDL-C Management in ACS Recovery** **Panel Discussion& Closing (10')** 劉如濟教授 (臺北醫學大學醫學系教授/衛生福利部雙和醫院副院長/心臟內科主治醫師)	長) **Opening remark(5')** 劉秉彥教授 (成功大學臨床醫學研究所教授/成大醫院內科部部主任/中華民國血脂動脈硬化學會理事長) **Lecture1. (25')** 張瑋婷副教授 (部定副教授/奇美醫院心臟血管內科主治醫師) 外泌體在心血管疾病的臨床應用 **Lecture2. (25')** 蕭世欣副教授 (臺北醫學大學醫學院副教授/附設醫院胸腔內科主治醫師及細胞治療中心主任) **Exosomes in Chronic Disease: A Clinical Application Overview** **Panel Discussion& Closing (5')** 劉嚴文教授 (成功大學醫學系教授/成大醫院心臟內科主治醫師及細胞治療中心主任)		
13:45-13:55	10 min	**Lunch Break II**						
		Main Session						

13:55-15:30	95 min	**Future Hospital-1 特色醫院** (附設醫院研究部)	**Post-ACS (PAC) 共識計畫研討** (附設醫院心臟內科/心血管研究中心) (台灣心肌梗塞學會合辦)	**泌尿疾患治療新進展** (附設醫院泌尿科)	**腦刺激** (附設醫院睡眠中心)	**整合醫學照護：從醫院到居家HAH** (附設醫院內科部/整合照護科) (臺灣醫院整合醫學醫學會協辦)	**人工智慧在臨床試驗應用的最新趨勢與倫理議題** (附設醫院研究部) (財團法人醫學研究倫理基金會/台灣臨床研究倫理審查學會合辦)	**Advance in Neuroscience 神經醫學新進展** (臺北神經醫學中心)
		Chairperson 許惠恒教授 (國立陽明交通大學及國防醫學院教授/國家衛生研究院特聘研究員及副院長) 吳麥斯教授 臺北醫學大學教授暨校長/衛生福利部雙和醫院腎臟內科主治醫師/台灣腎臟醫學會理事長)	**Chairperson** 謝宜璋教授 (長庚大學醫學系教授/心臟內科系主任/中華民國心臟學會秘書長/台灣心肌梗塞學會常務理事) 劉如濟教授 (臺北醫學大學醫學系教授/衛生福利部雙和醫院副院長/心臟內科主治醫師/台灣心肌梗塞學會理事)	**Chairperson** 盧星華教授 (臺北醫學大學醫學院教授/附設醫院副院長) 劉明哲教授 (臺北醫學大學醫學院教授/附設醫院泌尿科主任)	**Chairperson** 李信謙教授 (臺北醫學大學醫學院教授/附設醫院睡眠中心主任) 洪敬倫助理教授 (國立陽明交通大學醫學院助理教授/台灣臨床TMS腦刺激學會理事長) 張勳安教授 (國防醫學院醫學系教授/三軍總醫院精神醫學部兒童青少年精神科主任)	**Chairperson** 陳錫賢教授 (臺北醫學大學醫學院教授/附設醫院內科部及醫品部主任) 張景智副教授 (陽明大學內科學系副教授/台北榮民總醫院全人整合醫學科主任) 馬漢平副教授 (臺北醫學大學傷害防治學研究所副教授/衛生福利部雙和醫院副院長) 曾家琳醫師 (台灣大學附設醫院家庭醫學部主治醫師)	**Chairperson** 何橈通教授 (國立陽明交通大學榮譽教授/財團法人醫學研究倫理基金會董事長)	**Chairperson** 葉篤學副教授 (臺北醫學大學副教授/臺北神經醫學中心副院長/臺北醫學大學附設醫院教學部主任) 陳淑美副教授 (臺北醫學大學神經外科副教授/附設醫院神經外科醫師)
		Opening remark(5') 許惠恒教授 (國立陽明交通大學及國防醫學院教授/國家衛生研究院特聘研究員及副院長) **Lecture 1 (35')** 陳亮恭教授 (國立陽明大學醫學系教授/臺北市立關渡醫院長) **Smart Hospital Control Tower for Healthy Longevity** **Lecture 2 (35')**	**Opening remark(5')** 黃群耀教授 (臺北醫學大學醫學院教授/附設醫院副院長/台灣心肌梗塞學會理事長) **Lecture 1 (25')** 王宇澄副教授 (亞洲大學醫學暨健康學院副教授/亞大醫院內科部兼心臟內科主任) 共識計畫緣起與發展目標簡介-抗血小板藥物 **Lecture 2 (20')** 陳志維醫師	**Opening remark(5')** 盧星華教授 (臺北醫學大學醫學院教授/附設醫院副院長) **Lecture 1 (20')** 林登龍教授 (國立陽明大學醫學系教授/台北榮民總醫院泌尿科特約醫師) **Lecture 2 (20')** 楊晨洸助理教授 (部定助理教授/臺中榮民總醫院泌尿醫學部科主任)	**Opening remark(5')** 李信謙教授 (臺北醫學大學醫學院教授/附設醫院睡眠中心主任) **Lecture 1 (25')** **Prof. Joshua C. Brown (Assistant Professor of Psychiatry, Harvard Medical School, USA)** **The new development of rTMS** **Lecture 2 (25')** **Dr. Martha Koo**	**Opening remark(5')** 陳錫賢教授 (臺北醫學大學醫學院教授/附設醫院內科部及醫品部主任) **Lecture 1 (25')** 蔡岡廷助理教授 (部定助理教授/奇美醫院家庭醫學部部長) 整合照護新面貌: AI智慧科技和遠距醫療的進展 **Lecture 2 (25')** 蔡宏斌主任 (臺北市立聯合醫院中興院區	**Opening remark(5')** 何橈通教授 (國立陽明交通大學榮譽教授/財團法人醫學研究倫理基金會董事長) **Lecture 1 (35')** 陳育群教授 (國立陽明交通大學教授/台北榮民總醫院玉里分院副院長) AI臨床試驗及實務考量 **Lecture 2 (35')**	**Opening remark(5')** 葉篤學副教授 (臺北醫學大學副教授/臺北神經醫學中心副院長/臺北醫學大學附設醫院教學部主任) **Lecture 1 (40')** 郭博昭教授 (國立陽明交通大學腦科學研究所教授) AIOT驅動的遠距心電腦波同步監測系統設計與應用

		洪大川助理教授 (部定助理教授/馬偕紀念醫院總院副院長暨淡水馬偕醫院院長) **Panel Discussion (20')** 劉燦宏教授 (臺北醫學大學內科教授/台北市立萬芳醫院院長) 詹鼎正教授 (國立臺灣大學醫學院教授暨附設醫院老年醫學部主治醫師/附設醫院北護分院院長)	(臺北醫學大學附設醫院心臟內科主治醫師暨健康管理中心副主任) 血脂 (LDL-C)控制目標 / 藥物/追蹤間隔 **Lecture 3 (20')** 徐千彝副教授 (臺北醫學大學醫學院副教授/附設醫院心臟內科主治醫師暨研究部副主任) 心肌梗塞後預防心衰竭之治療策略 **Panel Discussion (20') &Closing remark (5'):** 謝宜璋教授 劉如濟教授 黃群耀教授	**Lecture 3 (20')** 周安琪醫師 (臺北醫學大學附設醫院泌尿科主治醫師) **Prostate cancer focal treatment** **Lecture 4 (20')** **Prof. Guiting Lin** **(林桂亭教授)** **(Professor of Urology, University of California, San Francisco, CA, USA)** **Discussion (10')** 劉明哲教授 (臺北醫學大學醫學院教授/附設醫院泌尿科主任)	**(Chair, Clinical TMS Society, CA, USA)** **The development of rTMS in the United States** **Lecture 3 (25')** **Dr. Leo Chen** **(Senior Research Fellow& lecturer, Monash University, Australia)** **The development of rTMS in Australia** **Discussion (15')** 洪敬倫助理教授 (國立陽明交通大學醫學院助理教授/台灣臨床TMS腦刺激學會理事長) 張勳安教授 (國防醫學院醫學系教授/三軍總醫院精神醫學部兒童青少年精神科主任)	整合醫學照護科主任/財團法人器官捐贈移植登錄及病人自主推廣中心執行長) 老有所安: 預立醫療決定與在宅統合照護之新進展 **Lecture 3 (25')** 楊智皓醫師 (萬芳醫院急診醫學科主治醫師/預防醫學暨社區醫學部副主任) 當急診跨出院門: 共築社區急性照護的安全網絡 **Emergency Care Beyond the Hospital: Building a Community-Based Safety Net for Acute Home Care** **Closing remark (5'):** 盛望徽教授 (台大醫學院教授/新竹臺大分院副院長)	邱文聰研究員 (中央研究院法律學研究所研究員及智財暨轉處處長) AI臨床試驗及法律考量 **Panel Discussion (20')** 張芳維副教授 (國防醫學院副教授/三軍總醫院婦產部生殖不孕科主任/台灣臨床研究倫理審查學會理事長)	**Lecture 2 (40')** 林明錦副教授 (臺北醫學大學醫學資訊研究所副教授/萬芳醫院副院長及神經外科專任主治醫師) 從腦波到意識:任務導向EEG在神經科學中的創性應用 **Discussion (10')** 陳淑美副教授 (臺北醫學大學神經外科副教授/附設醫院神經外科醫師)
15:30-15:45	15 min	**Coffee Break II**						
15:45-17:20	95 min	**Main Session**						
		Future Hospital-2 智慧醫院 (附設醫院研究部)	**健康風險預測** (附設醫院檢驗科)	**Navigation in modern dentistry 當代牙醫治療之導航應用** (附設醫院牙科部)	**Smart Nursing Valued Healthcare** (附設醫院護理部)	**NGS in infection disease** (附設醫院成人感染科)	**分散型藥品臨床試驗(DCT)之執行實務與倫理考量** (附設醫院研究部) (財團法人醫學研究倫理基金會/台灣臨床研究倫理審查學會合辦)	

		Chairperson 陳志鴻教授 (成功大學內科學科名譽教授/台南市立安南醫院主治醫師) 施俊明教授 (臺北醫學大學醫學院教授/附設醫院院長)	**Chairperson** 鄧豪恩主任 (臺北醫學大學附設醫院醫學檢驗科主任)	**Chairperson** 方致元副教授. (臺北醫學大學牙醫學院副教授/萬芳醫院口腔醫學部主任) 林芯宇主任 (臺北醫學大學附設醫院口腔醫學部牙髓病科主任) 吳家佑副教授 (臺北醫學大學牙醫學院副教授/附設醫院牙科部主任)	**Chairperson** 方震中執行長 (財團法人醫院評鑑暨醫療品質策進會執行長/台大醫院急診醫學部主治醫師兼毒物外傷科主任/台大醫學院副教授/台灣急診醫學會榮譽理事長) 蕭淑代副院長 (臺北醫學大學護理學系兼任講師/附設醫院副院長/中華民國護理師護士公會全國聯合會常務理事/台北市護理師護士公會理事長)	**Chairperson** 莊涵琄主任 (臺北醫學大學附設醫院成人感染科主任) 林秀真副教授 (臺北醫學大學醫學院副教授/附設醫院臨床病理科主任)	**Chairperson** 張芳維副教授 (國防醫學院副教授/三軍總醫院婦產部生殖不孕科主任/台灣臨床研究倫理審查學會理事長)	
		Opening remark(5') 陳志鴻教授 (成功大學內科學科名譽教授/台南市立安南醫院主治醫師) **Lecture 1 (35')** 江清泉教授 (台灣大學名譽教授/輔仁大學講座教授/附設醫院副院長) **MAC WARD: An Innovative Negative-pressure Isolation Ward** **Lecture 2 (35')** 林宗憲教授 (高雄醫學大學醫學系教授/附設中和紀念醫院副院長) **Implantation of Artificial Intelligence in Healthcare in KMUH** **Panel Discussion (20')** 魏柏立教授 (臺北醫學大學醫學院教授	**Opening remark(5')** 鄧豪恩主任 (臺北醫學大學附設醫院醫學檢驗科主任) **Lecture 1 (40')** 劉韻如博士 (臺北醫學大學精準健康中心研究員) **Lecture 2 (40')** 柯世祐主任 (衛生福利部雙和醫院雙和醫院急診重症醫學部急診醫學科副主任暨健康管理中心主任) **Discussion (10')** 鄧豪恩主任 (臺北醫學大學附設醫院醫學檢驗科主任)	**Opening remark(5')** 吳家佑副教授 (臺北醫學大學牙醫學院副教授/附設醫院牙科部主任) **Lecture 1 (30')** 黃彥文醫師 (萬芳醫院牙科部主治醫師) 我該使用動態導航嗎？以“標靶落點”來評估動態導航結果 **Should I use dynamic navigation system？Evaluation the implant precision by “target zone” concept.** **Lecture 2 (30')** 林均霈醫師 (台灣大學附設醫院牙髓病科兼任主治醫師/長木牙醫診所主治醫師) 根管導航行不行? **Guided Endodontics**	**Opening remark(5')** 蕭淑代副院長 (臺北醫學大學護理學系兼任講師/附設醫院副院長/中華民國護理師護士公會全國聯合會常務理事/台北市護理師護士公會理事長) **Lecture 1 (30')** 蔡佩珊教授 (台北醫學大學醫護理學院教授兼院長) 重塑護理：以價值為本的護理臨床與教育革新 **Lecture 2 (30')** 朱冠郁督導長 (台北醫學大學附設醫院護理部督導長) 醫院的智慧照護 **Lecture 3 (30')** **Prof. Erica Yu** **(Professor and the Associate Dean &**	**Opening remark(5')** 莊涵琄主任 (臺北醫學大學附設醫院成人感染科主任) **Lecture 1 (40')** 王復德教授 (部定教授/臺北醫學大學附設醫院成人感染科主治醫師/台灣感染管制學會理事長) **Clinical Metagenomics Next-Generation Sequencing (mNGS) for Infectious Diseases Diagnosis** **Lecture 2 (40')** 劉伯瑜副教授 (中興大學副教授/臺中榮民總醫院感染科科主任) 次世代定序在血流感染的應用. **Application of Next-Generation Sequencing in**	**Opening remark(5')** 張芳維副教授 (國防醫學院副教授/三軍總醫院婦產部生殖不孕科主任/台灣臨床研究倫理審查學會理事長) **Lecture 1 (35')** 汪志雄教授 (國防醫學院教授/國泰綜合醫院麻醉科主任/國泰醫院人體試驗審查委員會主委) 分散型臨床試驗之執行實務 **Lecture 2 (35')** 何橈通教授 (國立陽明交通大學榮譽教授/財團法人醫學研究倫理基金會董事長) 分散型臨床試驗之倫理考量	

		暨附設醫院副院長/台北癌症中心院長) 葉宏一教授 (馬偕醫學大學教授暨校長/臺北馬偕醫院主治醫師)		Lecture 3 (30') 林涵威醫師 (立威口腔顎面外科牙醫診所院長/亞東紀念醫院口腔顎面外科兼任主治醫師) 導航是選擇還是信念？ Is Navigation a Choice or a Philosophy?	Department Chair for Undergraduate Studies at Cizik School of Nursing at UTHealth Houston, USA) AI in Nursing相關主題對智慧疾病照護成效	Bloodstream Infections Discussion (10') 林秀真副教授 (臺北醫學大學醫學院副教授/附設醫院臨床病理科主任)	Panel Discussion (20') 林志翰理事 (中山醫學大學附設醫院人體研究發展辦公室副主任/台灣臨床研究倫理審查學會常務理事)	
17:20-17:30	10 min	Evening Break (海報頒獎典禮-2102教室) 張君照教授(臺北醫學大學醫學院教授/附設醫院副院長)/ 黃群耀教授(臺北醫學大學醫學院教授/附設醫院副院長/台灣心肌梗塞學會理事長)						

臺北醫學會研討會_議程摘要與講師簡歷(暫定)

課程地點：16 樓胡水旺

主題：Plenary lecture	
Opening Remarks:	
講師簡歷	**姓名**：**吳麥斯** **現職**：臺北醫學大學教授暨校長 衛生福利部雙和醫院腎臟內科主治醫師 台灣腎臟醫學會理事長 **簡歷**： 學歷：臺北醫學大學 醫學系 學士 (1985 畢) 經歷： Dr. Mai-Szu Wu, President and a professor of internal medicine at Taipei Medical University, is a renowned nephrology physician and currently the President of Taiwan Society of Nephrology. Wu focuses his research on renal cellular physiology and biology, clinical nephrology and renal replacement therapy, etc. In his managerial capacity as president of TMU, Wu leads the integration of medical services and informatics across the University and its four affiliated hospitals, as well as TMU's long-term care provision to help address the need of an aging population in Taiwan. **姓名**：**施俊明** **現職**：臺北醫學大學醫學院教授/附設醫院院長 **簡歷**： 學歷：2000-2005 臺北醫學大學醫學研究所博士 1982-1990 陽明大學醫學系學士 經歷： 2024.07- 臺北市立行愛住宿長照機構院長 2023.04- 臺北醫學大學附設醫院院長 2022.02- 臺北醫學大學醫學系內科學科教授
課程 1 Future Diagnosis -精準醫學(Precision medicine)： 從分子到臨床-打造精準醫療的系統操作架構(講題初擬)	
課程摘要(暫)	透過本次演講希望協助學員建立從分子知識到臨床應用的精準醫療操作框架，提高評估、整合與應用最新科技於醫療實務的能力。探討精準醫學如何藉由個體的分子與基因特徵，推動診斷與治療的高度個人化。從基因組學、蛋白質體學與代謝體學等多層次資料出發，超越傳統的「一體適用」理論，朝向精準照護邁進。將以臨床案例與研究資料為基礎，呈現從分子診斷到藥物設計、臨床篩選與療效監測的整合流程，並討論如何將分子標誌導入臨床決策，以提升治療精準度與病人預後。
講師	**姓名**：**龔行健** **現職**：中央研究院院士，國家衛生研究院榮譽研究員，臺北醫學大學講座教授

簡歷	**簡歷**： 學歷： 1975 美國加州理工學院化學系博士 1969 臺灣大學理學院化學系學士 經歷： 2018.01- 臺北醫學大學癌症生物學與藥物研發博士學位學程講座教授 2017.02-2017.09 國家衛生研究院分子與基因醫學研究所代理所長 2012.12-2017.12 國家衛生研究院分子與基因醫學研究所特聘研究員 2012.12-2015.12 國家衛生研究院院長 2008- 藥物研發博士學位學程加州大學戴維斯分校生化與分子醫學系特聘教授 1998-2012 美國加州大學戴維斯分校癌症中心副主任兼基礎研究主任 1998-2008 美國加州大學戴維斯分校生化與分子醫學系教授 1997-1998 國家衛生研究院分子與基因醫學研究組主任 1990-1998 美國凱斯西儲大學癌症中心基礎醫學研究副主任 1989-1998 美國凱斯西儲大學醫學系教授 1984-1988 美國凱斯西儲大學分子生物與微生物學系副教授/教授 1987-1988 中央研究院分子生物研究所客座教授 1978-1984 密西根州立大學生物化學助理教授/副教授 1976-1978 美國加州大學舊金山分校博士後研究員
課程 2 Future Treatment - 最新醫療發展： Challenge to Medical Innovation from Academia	
課程摘要	Our group has tried to develop medical innovation based Academia research. One of our trials is to develop plasmid DNA-based gene therapy. To promote angiogenesis in patients with critical limb ischemia (CLI) caused by peripheral artery disease, we focused on hepatocyte growth factor (HGF) as pro-angiogenic factors. After the success of phase III clinical trial, HGF gene therapy drug, Collategene, was conditionally approved by PMDA in Japan. In 2024, Phase II study in USA using Collategene was reported to be successful, and FDA approved Breakthrough Therapy to Collategene. In addition, we recently focused on the therapeutic vaccination which has extended its scope from infectious diseases to chronic diseases based on plasmid DNA technology. We also developed early detection of dementia using AI-based eye-tracking technology. Responding to the rapid rise in the number of dementia cases is becoming increasingly urgent. A great deal of medical evidence indicates that early diagnosis and timely intervention lead to beneficial outcomes. A diagnostic method for the easy and accurate detection of mild symptoms of dementia is necessary to provide early intervention. Thus, we have developed a novel cognitive assessment method that uses eye-tracking technology. The method involves tracking and recording the subject's gaze as they watch a series of task movies of about three minutes' duration and using the eye-tracking data to quantify the subject's cognitive function.

	The results correlate well with scores obtained using a conventional cognitive test (MMSE). This easy-to-administer cognitive assessment application for smart devices provides effective screening for early symptoms of dementia. This eye-tracking device to detect dementia was approved as SaMD (software as medical device) in 2023 at Japan. Moreover, we have developed new SaMD to evaluate sarcopenia. In this lecture, I will focus medical innovation based on Academia-driven technology.
講師簡歷	**姓名**：**Prof. Ryuichi Morishita** **現職**：Professor, Department of Clinical Gene Therapy, School of Medicine, The University of Osaka **簡歷**： Ryuichi Morishita, M.D., Ph.D., graduated Osaka University Medical School in 1987, and received Ph. D. from Osaka University in 1991. After following postdoctoral Fellow at Stanford University School of Medicine, he served as an Assistant Professor, Department of Geriatric Medicine, Osaka University Medical School from 1994 to 1998. Then, from 1998 to 2003, he was Associate Professor, Division of Gene Therapy Science, Osaka University Medical School. Then, he became Professor & Chairman of Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University Medical School from 2003 to present. Professor Morishita received over 20 awards from various academic societies including Harry Goldbratt Award in Council of High Blood Pressure, American Heart Association, Award in Japanese of Japan Medical Society, Sato Award in 27th annual meeting of the Japanese Circulation Society and Invitrogen-Nature-Biotechnology Award. Professor Morishita is currently on the editorial board of over 30 scientific journals including Open Medicine Journal (Editor-in-Chief), Gene Therapy, ATVB, Circulation and Hypertension. He has published over 450 original articles and review papers, primarily on gene therapy and molecular biology in cardiovascular disease. In addition, Professor Morishita is a Board Chairman of Japanese Society of Anti-Aging Medicine. He was Strategic Advisor of Headquarter for HealthCare Strategy (Chief is Prime Minister of Japan). He is also Special Advisor of Osaka Prefecture and Osaka City, and General Producer of Osaka HealthCare Pavillion in 2025 Osaka Kansai Expo.
課程 3 Future Hospital-人工智慧 AI/綠能： 再生能源與 AI 智慧：建構未來智慧綠能生態系統(講題初擬)	
課程摘要	本演講深入剖析 AI 與綠能的融合如何實際推動能源轉型與永續發展，並協助學員掌握技術應用、策略思維與環境平衡的關鍵要素，通過實務案例與技術解析，揭示 AI 與綠能的融合如何在智慧電網、再生能源與資料中心建設中發揮關鍵作用，並實踐「淨零 AI」與「智慧綠能網絡」的理念。內容包含：智慧電網與再生能源優化、設備維護與發電效

(暫)	率提升、AI 驅動的智慧資料中心、AI 本身的環境挑戰及綠色設計與永續策略。
講師簡歷	**姓名**：**戴建丞** **現職**：經濟部產業技術司簡任技正 **簡歷**： 學歷：臺北醫學大學細胞治療與再生醫學國際博士學位學程 臺北醫學大學醫學研究所 臺北醫學大學藥學系 經歷： 經濟部技術處科長/經濟部技術處技正/經濟部工業局技士/臺北市政府衛生局股長/經濟部智慧財產局簡任技正兼科長(支援經濟部技術處)/臺北市政府衛生局技士

課程地點：16 樓胡水旺

主題：Future Medical Education **未來醫學教育**	
課程： **Data-Driven Transformation in Medical Education: Global Trends and AMA's Vision for the Future**	
課程摘要	Medical education is undergoing a significant transformation, shifting from traditional, one-size-fits-all approaches to personalized, data-driven learning models. This course delves into the global trends influencing this change and examines the American Medical Association's (AMA) initiatives to shape the future of medical education. A key focus is the concept of Precision Education (PE), which leverages data and technology, including artificial intelligence (AI), to tailor learning experiences to individual needs. PE aims to enhance personalization, efficiency, and learner agency across the medical education continuum . The AMA has launched the Transforming Lifelong Learning Through Precision Education Grant Program, residency programs, and continuing medical education . These initiatives include the development of AI tools like Reconnect, which curates personalized educational content based on a physician's patient panel, and the TRACERs project, which automates real-time evaluations of trainee performance. By examining these developments, the course aims to equip participants with a comprehensive understanding of how data-driven approaches are reshaping medical education and preparing future physicians to meet the evolving needs of healthcare.
講師簡歷	**姓名**：**Prof. Kimberly Lomis** **現職**：Vice President for Medical Education Innovation, American Medical Association, USA **簡歷**：In that capacity, she guides the AMA ChangeMedEd® Initiative, partnering with medical schools, GME and CPD programs to impact over 30,000 medical learners across the United States. Themes of collaborative work include competency-based medical education, training in health systems science across the continuum, value-added roles for learners, development of master adaptive learners, coaching for health professionals, promoting diversity of the physician workforce and inclusive environments, addressing learner & faculty wellbeing, and change management. Dr. Lomis oversees the AMA's Precision Education portfolio of projects leveraging data and technology to personalize and enhance medical education across the continuum. Active in considering the impact of AI on medical education, Dr. Lomis leads AMA initiatives, visits institutions nationally and internationally to promote AI education, and serves as a subject matter expert for the US National Academy of Sciences, Engineering and Medicine. Prior to joining the AMA staff, Dr. Lomis previously served as Professor of Surgery and Associate Dean for Undergraduate Medical Education at Vanderbilt University School of Medicine and has held multiple national and international leadership roles in medical

	education.

課程地點：16 樓胡水旺

主題：Future Medical Education **未來醫學教育**	
課程： **從理念到制度：台灣 CBME 推動策略與學習成果評估架構** **From Concept to System: CBME Implementation Strategies and Outcome Assessment Framework in the Taiwan Society of Otorhinolaryngology–Head and Neck Surgery**	
課程摘要	To address the limitations of traditional time-based residency training and align with international trends in Competency-Based Medical Education (CBME), the Taiwan Society of Otolaryngology-Head and Neck Surgery has systematically implemented an outcomes-driven framework since 2017. This initiative integrates Entrustable Professional Activities (EPAs), milestones, and workplace-based assessments (WBAs) via the Joint Commission of Taiwan's EMYWAY platform. Beginning in 2021, the project utilized deep learning natural language processing (NLP) models, specifically Bidirectional Encoder Representations from Transformers (BERT), to evaluate the quality of over 34,000 narrative reflections and faculty feedback collected from 35 training hospitals. BERT outperformed other models, achieving 85–92% accuracy and drastically reducing the time required to analyze 10,000 entries from 2,500 minutes manually to just 2.5 minutes automatically. Between 2021 and 2025, the proportion of high-quality reflections and feedback improved markedly (resident: 70.3%→99.5%; faculty: 50.6%→88.9%), with participation and timely completion rates also rising (3-day feedback rate: 40.1%→86.4%). Moreover, the implementation of national Clinical Competency Committees (CCCs) further standardized EPA-based summative entrustment decisions across all training sites. The initiative not only optimized the teaching and assessment process but also catalyzed cultural change toward reflective, data-informed education. This system-wide transformation demonstrates the feasibility and impact of integrating AI-powered evaluation tools with structured CBME strategies, enabling scalable, real-time quality assurance in postgraduate medical education. The project serves as a national model for specialty-specific CBME implementation and highlights future directions such as real-time BI dashboards and cross-institutional analytics for continuous educational improvement.
講師簡歷	**姓名**：**陳正文** **現職**：Deputy Superintendent of Administration, Cardinal Tien Hospital (2023–Present) Director, Human Research Protection Center, Cardinal Tien Hospital (2022–Present) Chief Information Security Officer (CISO), Cardinal Tien Hospital (2023–Present) Chief Sustainability Officer (CSO), Cardinal Tien Hospital (2023–Present) Executive Secretary, Institutional Review Board, Cardinal Tien Hospital (2022–Present) Associate Professor, School of Medicine, College of Medicine, Fu Jen Catholic University (2005–Present)

	Visiting Staff, Department of Otolaryngology–Head and Neck Surgery, Cardinal Tien Hospital (2002–Present) Adjunct Assistant Professor, Department of Otolaryngology–Head and Neck Surgery, National Taiwan University Hospital (1997–Present) Convener, Department of Otolaryngology–Head and Neck Surgery, National Health Insurance Dispute Review Committee, Ministry of Health and Welfare (2006–Present) Consultant, CBME Application and Information Development Committee, Joint Commission of Taiwan (JCT) (2023–Present) Convener, CBME Core Subcommittee, Taiwan Society of Otorhinolaryngology–Head and Neck Surgery (TSOHNS) (2022–Present) **簡歷**： Dr. Jeng-Wen Chen is a clinician-scholar with over 30 years of experience in otorhinolaryngology–head and neck surgery. He serves as Deputy Superintendent of Administration, Chief Information Security Officer, and Chief Sustainability Officer at Cardinal Tien Hospital, where he also directs the Human Research Protection Center and IRB. He is also an Associate Professor at Fu Jen Catholic University and an Adjunct Assistant Professor at National Taiwan University Hospital. Dr. Chen earned his MD from Kaohsiung Medical University, an MS in Biomedical Big Data Analysis, and is currently pursuing a PhD in Business Administration. In 2025, he was promoted to Associate Professor by the Ministry of Education. Clinically, Dr. Chen has led the Department of Otolaryngology at Cardinal Tien Hospital and has contributed to Taiwan's healthcare policy through the National Health Insurance Dispute Review Committee. He plays a central role in medical education reform as Convener of the Core CBME Subcommittee of the Taiwan Society of Otorhinolaryngology and a consultant to the Joint Commission of Taiwan. A prolific researcher, Dr. Chen has authored over 50 peer-reviewed articles in journals such as The Laryngoscope, Otolaryngology–Head and Neck Surgery, and Cancer Medicine, covering sleep-disordered breathing, AI models, CBME, and Entrustable Professional Activities. He has led multiple national projects on educational innovation and clinical epidemiology. He has received the Tech Innovation Excellence Award and the Symbol of National Quality Award and serves as a peer reviewer for 40+ journals. His current research focuses on CBME systems, AI in clinical education, and ultrasound applications in ENT.

課程地點：16 樓胡水旺

主題：Future Medical Education **未來醫學教育**	
課程： **在地實踐的挑戰與創新：教學現場如何落實 CBME 與數據學習** **Local Implementation of CBME: Lessons, Challenges, and Innovations in Clinical Teaching Settings.**	
課程摘要	隨著教育模式轉向能力導向（Competency-Based Medical Education, CBME），教學現場面臨調整挑戰與機會。本次演講聚焦於 CBME 架構應用實務、在地實作與反思及創新工具與平台應用，深入探討學習者能力評量指標設定、課程設計與教學策略，並結合臨床情境強化學生核心能力，並介紹如何收集與分析學習者學習歷程、評量結果與反饋，透過可視化儀表板支援教師即時掌握學情，透過在台灣（或特定教學場域）試點案例，解析文化、資源、評量系統差異所導致的調適需求與策略反思。 本課程由理論、系統設計、工具實作與場域分析四大面向組成，旨在培養具備 CBME 核心素養並能善用數據分析的教學專業者，進一步推動課程改革與教學創新。
講師簡歷	**姓名：陳建宇** **現職：**臺北醫學大學醫學系醫學教育暨人文學科教授/臺北醫學大學副教務長/附設醫院麻醉科主治醫師 **簡歷：** 學歷 2020-2021 美國加州史丹佛大學史丹佛醫學院客座副教授 2007-2012 英國布里斯托大學醫學倫理教育博士 1992-1999 臺北醫學大學醫學系學士 經歷 2025.02- 臺北醫學大學醫學系醫學系醫學教育暨人文學科教授 2023.09- 臺北醫學大學教師發展中心主任 2023.08- 臺北醫學大學副教務長 2023.02-2025.01 臺北醫學大學醫學系醫學系醫學教育暨人文學科副教授 2021.08-2024.07 臺北醫學大學醫學系醫學教育暨人文學科主任 2017.08-2023.08 臺北醫學大學附設醫院教學部主任 2018.08-2023.02 臺北醫學大學麻醉學科副教授 2015.02-2018.07 臺北醫學大學醫學系麻醉學科助理教授 2013.04-2015.01 臺北醫學大學醫學人文研究所助理教授 2000.08-2005.06 臺大醫院住院醫師

課程地點：4 樓誠樸廳

主題：潛龍之用：龍年世代對精準醫學的貢獻	
課程： **Polygenetic risk score for breast cancer screening (tentative)**	
課程摘要	Polygenic Risk Scores (PRS) aggregate the effects of multiple common genetic variants to estimate an individual's genetic predisposition to breast cancer. Incorporating PRS into breast cancer screening allows for a more personalized approach, identifying individuals at higher risk who might benefit from earlier or more frequent screening, as well as those at lower risk who may avoid unnecessary procedures. This course provides an overview of PRS methodology, including its calculation and interpretation. Participants will explore how PRS can complement traditional risk factors such as family history and mammographic density to refine screening strategies. The course will also discuss the integration of PRS into clinical practice, examining current guidelines and the potential for personalized screening protocols. Through case studies and current research findings, attendees will gain insights into the practical applications and limitations of PRS in breast cancer screening. The course aims to equip healthcare professionals with the knowledge to incorporate genetic risk information into patient care, enhancing early detection and prevention strategies.
講師簡歷	**姓名**：**邵于萱** **現職**：台北醫學大學健康數據研究中心主任 **簡歷**： 學歷 2008 羅格斯大學公共衛生學院流行病學博士 2000 約翰霍普金斯大學公共衛生碩士 1998 臺北醫學大學公共衛生學系學士 經歷 2025.01- 臺北醫學大學數據處副數據長 2022- 臺北醫學大學數據處健康資料加值暨統計中心主任 2020- 臺北醫學大學醫學資訊研究所教授 2014-2020 臺北醫學大學醫學資訊研究所副教授 2014-2020 Adjunct Associate Professor, Rutgers School of Public Health 2012 Assistant Professor, Robert Wood Johnson Medical School

課程地點：4 樓誠樸廳

主題：潛龍之用：龍年世代對精準醫學的貢獻	
課程： **Honeybear: Approaching Radiopharceutical Antibody Drug Conjugate (tentative)**	
課程摘要	HoneyBear Biosciences specializing in the development of innovative antibody-drug conjugates (ADCs), particularly focusing on Antibody-Radionuclide Conjugates (ARCs) for targeted cancer therapy. The company's proprietary CoNectar™ platform utilizes site-specific glycan conjugation to precisely attach dual payloads to antibodies, enhancing therapeutic efficacy and reducing resistance. In collaboration with Singapore's Agency for Science, Technology and Research (ASTAR), HoneyBear has secured exclusive licenses to develop ARCs using antibodies from ASTAR's Singapore Immunology Network (SIgN) and non-exclusive rights to utilize A*STAR's multicistronic expression vector technology for efficient antibody production. This partnership aims to advance ARC development and improve cancer treatment outcomes. The course will delve into the principles of ARC technology, the advantages of dual payload delivery, and the integration of CoNectar™ with A*STAR's technologies. Participants will gain insights into HoneyBear's pipeline, including the development of ARC candidates targeting various cancers.
講師簡歷	**姓名**：**莊士賢** **現職**：嘉正生技技術長 **簡歷**： https://news.gbimonthly.com/tw/invest/show2.php?num=1223

課程地點：4 樓誠樸廳

主題：潛龍之用：龍年世代對精準醫學的貢獻	
課程： **Artificial intelligence in precision healthcare (tentative)**	
課程摘要	With the rapid advancement of artificial intelligence (AI) technologies, AI is increasingly applied in precision medicine, profoundly impacting disease prevention, diagnosis, treatment, and prognostic management. This course aims to introduce the core applications of AI in precision medicine, including biomedical data analysis, medical imaging processing, genomic data interpretation, and personalized treatment strategy formulation. Participants will learn how to utilize AI technologies for disease risk prediction, early diagnosis, treatment efficacy forecasting, and therapeutic monitoring, and explore practical case studies of AI applications in clinical practice. The course content covers foundational AI knowledge, machine learning and deep learning algorithms, medical image analysis techniques, and genomic data processing methods. Through practical case analyses, participants will gain insights into the value and challenges of AI applications in precision medicine. Additionally, the course will discuss ethical considerations, privacy protection, and regulatory issues related to AI applications in healthcare, enhancing participants' comprehensive understanding of AI applications.
講師簡歷	**姓名**：**連加恩** **現職**：宏碁智醫董事長 **簡歷**： https://www.acer-medical.com/ch/2024/01/31/%E3%80%90%E9%81%A0%E8%A6%8B%E5%B0%88%E8%A8%AA%E3%80%91%E9%80%A3%E5%8A%A0%E6%81%A9%E4%B8%8D%E7%95%B6%E9%86%AB%E7%94%9F-%E4%BD%86%E8%A6%81%E5%B8%B6%E6%99%BA%E6%85%A7%E9%86%AB%E7%99%82%E8%B5%B0%E5%90%91/

課程地點：2101 教室

主題：兒童手術-從微創到機器人	
課程： **My Journey of MIS in Pediatric Biliary Diseases**	
課程摘要	My journey with minimally invasive surgery (MIS) in pediatric biliary diseases began in 2007 at the National Children's Hospital, Hanoi, Vietnam. At that time, our team was led by Professor Nguyen T. Liem. Initially, we performed laparoscopic total excision of choledochal cysts followed by hepatico-duodenostomy (HD), with our first report published in 2009. Subsequently, we performed both hepatico-duodenostomy and hepatico-jejunostomy (HJ), and in 2012, we reported our experience with 400 cases. In 2012, I started performing transumbilical laparoendoscopic single-site surgery (TULESS), also known as single-incision laparoscopic surgery (SILS), for choledochal cysts. We reported the early outcomes of 86 cases in 2014. Our team also began laparoscopic Kasai porto-enterostomy for biliary atresia in 2008, with our first report published in 2010. A randomized clinical trial conducted at our center examined the long-term outcomes, which were published in 2023. Additionally, I have been using MIS techniques in more complex pediatric biliary cases, such as laparoscopic hepatic ductoplasty and redo surgeries for complicated choledochal cysts and biliary atresia.
講師簡歷	**姓名**：**Pro.Tran Ngoc Son** **現職**：Deputy Director of Saint Paul General Hospital in Hanoi, Vietnam **簡歷**： Dr. Ngoc Duc Tran graduated from Thai Binh Medical University with a General Practitioner degree in 2008. In 2017, he earned another degree in Radiology from Hanoi Medical University and became a Master of Medicine in 2018. He attended training courses in Japan and Vietnam at Saint Paul Hospital by French experts, then became an Interventional Radiologist at the same hospital from 2009 to 2010. In 2016 he was in charge of the Interventional Diagnosis Unit at the High-tech Center for Digestive System of Hanoi. He has performed thousands of cases of burning high-frequency waves to treat thyroid nodules, liver cancer, and breast fibroadenoma at many leading hospitals in Hanoi, Vietnam

課程地點：2101 教室

主題：兒童手術-從微創到機器人	
課程： **Evolution of MIS for Biliary Diseases: Taiwan Experience**	
課程摘要	In this course, I share my experiences and insights into the evolution of minimally invasive surgery (MIS) for biliary diseases in pediatric patients, focusing on the advancements and challenges encountered in Taiwan. These procedures have significantly reduced recovery times and improved cosmetic outcomes, aligning with global trends toward less invasive surgical approaches. Through this course, I aim to provide participants with a comprehensive understanding of the evolution of MIS in pediatric biliary diseases, sharing both the technical aspects and the collaborative efforts that have contributed to our progress. By examining case studies and discussing the challenges faced, I hope to inspire and equip fellow healthcare professionals to advance the field of pediatric surgery in Taiwan and beyond.
講師簡歷	**姓名**：**傅玉璋** **現職**：彰化基督教醫院兒童外科主治醫師 **簡歷**： 學歷： 中國醫藥大學醫學士 經歷 台北馬偕紀念醫院外科部住院醫師 台北馬偕紀念醫院小兒外科總住院醫師 台北馬偕紀念醫院小兒外科主治醫師 韓國首爾延世大學附設醫院達文西機械手臂內視鏡手術訓練 國際小兒內視鏡外科會員（International Pediatric Endosurgery Group） 美國費城兒童醫院泌尿科進修 美國波士頓兒童醫院泌尿科進修

課程地點：2101 教室

主題：兒童手術-從微創到機器人	
課程： **MIS for Choledochal Cyst in National Taiwan University Children Hospital**	
課程摘要	At National Taiwan University Children's Hospital, our approach to minimally invasive surgery (MIS) for choledochal cysts has evolved significantly over the past decade. While hepaticojejunostomy was the preferred reconstruction in earlier years, we have transitioned to hepaticoduodenostomy in most cases over the past five years. In this presentation, I will review our institutional experience, outline the rationale behind this shift in surgical strategy, and share data on patient outcomes. I will also highlight our recent technical refinements in MIS according to recent evidence.
講師簡歷	**姓名**：**洪琬婷** **現職**：Attending surgeon, Division of Pediatric Surgery, Department of Surgery, National Taiwan University Hospital 臺大醫院外科部小兒外科主治醫師 Clinical Assistant Professor, Department of Surgery, College of Medicine, National Taiwan University 臺大醫學院外科臨床助理教授 **簡歷**： Dr. Wan-Ting Hung is a board-certified pediatric and thoracic surgeon at National Taiwan University Children's Hospital. With dual training in both specialties, Dr. Hung brings a unique perspective to pediatric surgical care, particularly in the field of minimally invasive thoracic surgery. Her clinical and academic work focuses on refining surgical techniques and enhancing recovery protocols for young patients

課程地點：2102 教室

主題：醫療創新與 AI 應用	
課程： **掌握人心的簡報藝術**	
課程摘要	As an investor, every year hundreds of people tell me their stories in the hope of securing money from our venture capital funds. Before this, I was the one helping startup companies tell stories to raise over a hundred million from investors. And before that, I was helping national leaders, mayors, and nobel laureats tell their stories. After all this experience, I think the secret to giving a great presentation, or telling a great story if you will, isn't what you think, or what most people say it is. In this talk, I hope to explore with you where the secret may lie…
講師簡歷	**姓名**：**楊為植** **現職**：Senior Director, Darwin Ventures **簡歷**： Andrew joined Darwin Venture Management in 2022. He comes from the diplomacy world, where he served with Nobel Laureate Prof. YT Lee in the International Science Council, and then joined Taiwan's Presidential Office in 2016 as foreign policy speechwriter to the president and vice president. In a career pivot, Andrew entered the startup world. He joined the venture capital arm of the renowned Industrial Technology Research Institute (ITRI), and also co-founded the Presentality agency to help startups and public companies craft their fundraising and communication strategy, successfully raising over $100m in funding. In 2020, Andrew also worked with industry leaders from Wistron, Qisda, Fubon, etc. to start the Taiwan Renaissance Platform, utilizing white papers and summits to promote corporate venture capital in Taiwan. Andrew grew up in Taiwan, Europe and the United States, and speaks English, Mandarin, French, and German. He received his B.A. in International Affairs from the University of Wisconsin-Madison, and his M.A. in Law and Diplomacy from the Fletcher School.

課程地點：2102 教室

主題：醫療創新與 AI 應用	
課程： **生成式 AI：增進職場效率好幫手**	
課程摘要	在醫療現場中，無論是撰寫衛教單張、交接班記錄，還是查詢臨床指引，這些日常重複卻重要的任務，正是生成式 AI 最能發揮效益的地方。 本場講座將透過三個「你我都做過」的情境，快速示範生成式 AI 如何成為醫護人員的好幫手： 衛教資料製作： 一鍵產出高血壓、糖尿病等常見病症的個人化圖文衛教單張 語音轉文字＋摘要： 協助整理交班錄音、病房會議重點，省下打字與彙整時間 臨床知識查詢： 善用 AI 搜尋引擎（如 Perplexity）輔助理解新指引、複雜診斷選項 講者將以臨床友善的語言、實際操作畫面，帶領參與者認識這些工具的應用方法與使用眉角，幫助現場醫護人員打開 AI 的第一扇門，在不額外增加負擔的前提下，讓效率與專業同步升級。
講師簡歷	**姓名**：**張可佳** **現職**：星創智慧科技 CTO **簡歷**： Claire 擁有豐富的全端開發與生成式 AI 實戰經驗，專精影像辨識與工作流程自動化，致力於以 AI 賦能開發者與職場工作者。 活躍於科技女性社群，曾擔任多場技術社群活動講者與主持，擅長以深入淺出的方式傳遞技術知識，結合實際案例與現場演練，引導學員探索 AI 工具於開發、學習與職場效能提升的多元應用。 教學風格兼具邏輯與親和力，擅長結合應用示範與引導反思，協助學員將學習落實為行動，實現「讓 AI 成為你職涯超神助手」的理念。

課程地點：2102 教室

主題：醫療創新與 AI 應用	
課程： **Implementation Cases of AMR and Physical AI in Healthcare Applications**	
課程摘要	Originating during the COVID-19 pandemic, ADATA Technology collaborated with National Taiwan University Hospital to launch autonomous disinfection robots to assist hospitals with environmental sanitization, marking ADATA's entry into smart healthcare applications. In light of Taiwan's declining birthrate, aging population, and increasing strain on medical personnel, applying AI and automation technologies in hospital environments has become a critical issue to alleviate the workload of healthcare professionals. At this year's Computex, ADATA unveiled a tripartite collaboration with NVIDIA and Advantech, utilizing NVIDIA Omniverse and Cosmos to build digital twin models of hospital environments. By leveraging Isaac technologies to train AMRs (Autonomous Mobile Robots) for navigation and obstacle avoidance, combined with Jetson Orin edge AI computing units and Advantech IPCs, the team successfully developed smart hospital solutions such as intelligent surgical instrument transporters, smart nursing carts, and ward inspection robots. In the future, these solutions can be further integrated with medical-grade wearable devices to automatically transmit patients' physiological data to nursing stations, significantly reducing the workload on medical staff and preparing Taiwan for an aging and longevity-focused society.
講師簡歷	**姓名**：**林昭陽** **現職**：EVP, ADATA Technology Co., Ltd. **簡歷**： Since joining the Telecommunications Laboratories of the Ministry of Transportation and Communications in 1987 (later reorganized as Chunghwa Telecom Laboratories), I have cultivated over 30 years of experience in the ICT industry. As a technically grounded leader, I have always adhered to the belief that "technological innovation is the foundation, and practical implementation is the core." I am committed to advancing AI, cloud computing, cybersecurity, and large-scale information system integration and applications, aiming to bring substantial value and sustainable momentum to Taiwan's ICT sector. I earned my Ph.D. in Electronic Engineering from National Taiwan University of Science and Technology, specializing in artificial intelligence and computer systems. As early as the 1990s, I focused my doctoral research on AI and have continued to apply AI technologies throughout my career to transform Chunghwa Telecom's operations and optimize its services. Over the years, I have held key positions including Director of Chunghwa Telecom Laboratories and President of the Information Technology Business Group. In 2023, I assumed the role of President of Chunghwa Telecom, where I spearheaded the company's digital transformation strategy, driving initiatives such as the implementation of generative AI, the establishment of

	AI computing resource pools, and strategic collaborations with leading global chip manufacturers like NVIDIA and AMD. During my tenure, I launched the "AI 2.0 Strategic Committee" to integrate AI and ICT services across the company—from automating internal workflows and enhancing customer service to upgrading enterprise cloud applications—realizing technology commercialization and tangible business outcomes. I also championed a multi-layered cybersecurity framework, including HiNet WAF, ANDs intrusion prevention, and SOC monitoring systems, strengthening the digital resilience of both enterprises and government agencies. Beyond the enterprise, I have contributed to public-private partnerships and industry development. As Chairman of Information Technology Total Services (ITTS), I led the company to record-breaking revenue and profits. I also served as a board member of the Institute for Information Industry (III), advancing Taiwan's ICT policy and development initiatives. Since retiring as President of Chunghwa Telecom in 2024, I have remained actively engaged in research, consulting, and industry-academia collaborations, with a vision to leverage my expertise and insights to further Taiwan's digital transformation, technology policy, and innovation adoption. Looking back, I have always believed that the true value of technology lies not in the technology itself, but in its impact on people's lives, industry development, and societal progress. Moving forward, I remain dedicated to contributing my knowledge and experience to create meaningful value in the era of the digital economy.

課程地點：2103 教室

主題：智慧醫療 品質到價值	
課程： **Rethinking Innovation in Healthcare: Truths, Challenges, and Game Changers**	
課程摘要	In this course, I will present our work on HoloMedicine and the development of digital twins, initiatives designed to enhance pre-surgical planning and intra-operative navigation through mixed reality and personalized 3D anatomical models. Successful integration of these advanced technologies requires close collaboration among clinicians, engineers, and data scientists to develop solutions that are both technically feasible and clinically relevant. Delving into the complexities of healthcare innovation, I emphasize the need for a balanced approach that combines technological advancements with human-centered design and evidence-based implementation. While technology holds great promise for revolutionizing healthcare, it is not a cure-all. Challenges such as data quality, algorithmic biases, and unintended psychological and social effects on patients and providers must be thoughtfully addressed to achieve meaningful and sustainable improvements. A significant part of the discussion focuses on “disruptive” innovations like telehealth. Although these technologies improve convenience and accessibility, they often do not fundamentally change patient behavior over time. Therefore, it is more valuable to identify specific, high-impact use cases rather than pursuing broad, game-changing applications that may not deliver the desired outcomes.
講師簡歷	**姓名**：**Adj Asst Prof. GAO Yujia** **現職**：Adjunct Assistant Professor and Director of Undergraduate Medical Education, Department of Surgery, Yong Loo Lin School of Medicine, NUS; Principal Investigator, iHealthTech, NUS, Singapore **簡歷**： Designations: Consultant, Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery, National University Hospital Consultant, Adult Liver Transplantation Programme, National University Centre for Organ Transplantation, National University Hospital Qualifications: MBBS (S'pore), MRCS (Edinburgh), DFD (CAW)(S'pore), MMed (Surgery)(S'pore), FRCS Ed (Gen Surgery)(Edinburgh) Specialties/Sub-specialties: General Surgery Clinical Disciplines/Programmes: Adult Liver Transplantation Programme, Hepatobiliary & Pancreatic Surgery, Hepato-Pancreato-Biliary Surgery & Liver Transplantation, Organ Transplantation Special Interests: Hepatobiliary & Pancreatic Surgery

課程地點：2103 教室

主題：智慧醫療 品質到價值	
課程： **醫院智慧醫療規劃與提升品質與病安的影響**	
課程摘要	隨著智慧醫療迅速融合 AI、IoT、HIT 技術，醫院面臨整體品質與病人安全的轉型需求。本次演講以智慧醫療系統規劃與治理、提升醫療品質與安全實務、創新技術與流程最佳化、及實務挑戰與策略應用為架構，探討醫療資訊管理策略、風險識別、評鑑法規、HIT 認證與通報機制，介紹科技介入如何減少藥物錯誤、不良事件與處方漏洞，說明 AI 影像判讀、5G 遠距監測、RFID 設備追蹤、智能環境監控，如何提升診斷精準度、流程效率與降低人為疏失。本課程整合治理架構、關鍵技術與在地挑戰，旨在提升教學醫院及區域醫院對智慧醫療策略的規劃能力，從而真正強化醫療品質與病人安全。
講師簡歷	**姓名**：**譚慶鼎** **現職**：國立臺灣大學醫學院耳鼻喉科教授/附設醫院新竹臺大分院副院長/耳鼻喉部主治醫師 **簡歷**： 學歷 北一女中 中山醫學院醫學系 台大醫學院毒理學博士 台灣大學 EMBA 資管組碩士 經歷 羅東博愛醫院耳鼻喉科主任 臺大醫院口腔咽喉科主任 日本東京大學音聲言語研究中心研修 1996- 美國約翰霍普金斯大學耳鼻喉科觀察員 2000- 法國巴黎第七大學醫學院耳鼻喉科研究員 1994-1995

課程地點：2103 教室

主題：智慧醫療 品質到價值	
課程： **運用智慧醫療工具改善心臟疾病病人照護結果**	
課程摘要	本場演講將說明北醫團隊如何運用智慧醫療工具，建構從住院到出院後的整合性照護流程。透過診間決策輔助系統、LINE 衛教訊息推播、single-pill combination 藥物策略，以及遠距心律與血壓監測，提升 ACS 病人 LDL-C 達標率並降低再入院風險。從個案管理到演算法導入，本團隊實證展示智慧科技在臨床中有效落實「以病人為中心」的照護目標，實現從品質走向價值的實質轉譯。
講師簡歷	**姓名**：**陳志維** **現職**：臺北醫學大學附設醫院心臟內科主治醫師暨健康管理中心副主任 **簡歷**： 學歷 2004-2011 中山學醫學大學醫學士 經歷 2024.03- 臺北醫學大學附設醫院健康管理中心副主任 臺北醫學大學附設醫院住院醫師、主治醫師 2022.08- 臺北醫學大學醫學系內科學科講師 2012.08-2013.07 臺北榮民總醫院住院醫師

課程地點：2104 教室

主題：腎絲球腎炎研討	
課程： **Update on IgA nephropathy management: insight from KDIGO 2025 guideline**	
課程摘要	IgA nephropathy (IgAN) remains the most prevalent primary glomerulonephritis worldwide, with significant heterogeneity in presentation and progression. Approximately 30% to 45% of patients progress to kidney failure within 20 to 25 years after diagnosis, and effective treatment has long been lacking. With deeper understanding of the pathogenesis of IgA nephropathy—including the roles of the mucosal immune system, B cells, complement system, and endothelin system—therapeutic development in this field is advancing rapidly. This presentation will review the latest advancements in the diagnosis and clinical management of IgA nephropathy, aiming to achieve precision in diagnosis and treatment, and to improve patient outcomes and quality of life. The 2025 update of the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases introduces key advancements in the risk stratification, treatment algorithms, and therapeutic targets specific to IgAN. This session will provide a concise yet comprehensive overview of the updated KDIGO recommendations, focusing on the rationale behind new guidance and the incorporation of recent clinical trial data. Emphasis will be placed on the role of the updated MEST-C score, individualized risk prediction using the International IgAN Prediction Tool, and a stepwise therapeutic approach that balances supportive care with immunomodulatory therapies. Special attention will be given to the integration of novel agents such as targeted-release budesonide, complement inhibitors, and SGLT2 inhibitors into clinical practice. Strategies for patient-centered care, including management in special populations and shared decision-making in the context of evolving evidence, will also be discussed.
講師簡歷	**姓名**：**吳逸文** **現職**：MD, Taipei Medical University Hospital; Associate Professor, Taipei Medical University **簡歷**： Dr. I-Wen Wu graduated from the College of Medicine, University of Buenos Aires, Argentina and completed nephrologist training at Chang Gung Memorial Hospital, Taiwan. She has been a Clinical Professor of Nephrology at Chang Gung Memorial Hospital. She is currently the Director of Division of Nephrology and the Department of Medical Research at TMUH. She also serves as an Associate Professor of Internal Medicine at Taipei Medical University. Dr. Wu is devoted to promoting knowledge exchange and international collaboration between TSN and different academic societies worldwide. Her research interests are focused on the area of prevention and prediction of CKD and multi-omics biomarkers, specifically in areas of microbiota and uremic toxins. She is the National Leader of various clinical trials for renal anemia, glomerulonephritis, and novel drugs focusing on renal

	outcomes. She receives research grant support from the Ministry of Science and Technology of Taiwan in the areas of uremic toxins and microbiota. She has published over 120 articles in international peer-reviewed journals and written chapters for the Taiwan Renal Database System and the Taiwan CKD clinical guidelines.

課程地點：2104 教室

主題：腎絲球腎炎研討	
課程： **Insights from the Taiwan Renal Biopsy Registry: Observational Findings on Immunoglobulin A Nephropathy**	
課程摘要	Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and represents a leading cause of chronic kidney disease in East Asia. The Taiwan Renal Biopsy Registry, a national data repository, systematically collects clinicopathological data from renal biopsies performed across Taiwan, offering a valuable opportunity to analyze disease patterns，yet outcome data were not available. This presentation aims to summarize observational research findings on IgAN from the Taiwan Renal Biopsy Registry, highlighting demographic features, clinicopathologic correlations. In addition, a hospital based analysis was performed for outcome prediction for IgAN. Methods: We conducted a retrospective analysis of registry data involving patients diagnosed with IgAN. Variables included patient age, sex, laboratory findings, and histopathologic classification. We also report the therapeutic interventions, and renal function trajectory associatedwith adverse outcomes.
講師簡歷	**姓名**：**黃道民** **現職**：Attending Physician Department of Internal Medicine (Nephrology and Intensive Care Consultation), National Taiwan University Hospital and College of Medicine Secretary General Society of Emergency and Critical Care Medicine (TSECCM) Taipei City, Taiwan. **簡歷**： Dr. Thomas Tao-Min Huang is an attending physician specializing in nephrology and critical care medicine at the National Taiwan University Hospital (NTUH) and a clinical lecturer in the College of Medicine, National Taiwan University. He received his MD degree from the College of Medicine, National Taiwan University in 2003, and completed his residency in internal medicine at NTUH in 2007. Following fellowships in nephrology and critical care medicine, Dr. Huang has devoted his career to advancing care for patients with acute and chronic kidney diseases, as well as critically ill patients in the intensive care unit. From 2009 to 2016, Dr. Huang served as an attending physician at the NTUH Yunlin Branch, where he also held leadership positions as Chief of the Center for Quality Management and Chief of the Center for Dialysis. Since 2016, he has worked at the NTUH main campus in

	Taipei, providing high-level care and supervising trainees. He is board-certified in internal medicine, nephrology, and critical care medicine, and holds a national medical license in Taiwan. Dr. Huang is an active member of several national and international societies, including the Taiwan Society of Nephrology, the Taiwan Society of Critical Care Medicine, the International Society of Nephrology, and the Asia-Pacific Society of Nephrology. His dedication to medical education is reflected in numerous teaching roles, including board examination instruction and OSCE examiner responsibilities. Dr. Huang has authored or co-authored over 70 peer-reviewed publications and has presented at international scientific meetings. His research interests focus on acute kidney injury, dialysis outcomes, critical care nephrology, and registry-based observational studies in glomerular diseases, including IgA nephropathy. Throughout his career, Dr. Huang has received multiple honors for excellence in clinical performance, research, and teaching, underlining his ongoing commitment to improving patient care and advancing the field of nephrology.

臺北醫學會研討會_議程摘要與講師簡歷(暫定)

課程地點：2104 教室

主題：腎絲球腎炎研討	
課程： **Novel biomarkers of IgA Nephropathy**	
課程摘要	IgA nephropathy (IgAN) is the leading primary glomerulonephritis, with a concerning 40% of patients progressing to end-stage renal disease within two decades of diagnosis. Therefore, identifying those at risk of progression to facilitate earlier aggressive treatment is paramount. While kidney biopsy remains the definitive diagnostic method, existing prognostic markers—including histopathologic findings, proteinuria, glomerular filtration rate, and hypertension—though validated, lack the specificity to inform treatment decisions. Similarly, the Oxford classification's pathologic MEST-C score does not provide sufficient guidance. The "four-hit hypothesis" of IgAN pathophysiology offers a framework for understanding the disease and, critically, for discovering new biomarkers. Encouragingly, several promising biomarkers are emerging, such as galactose-deficient IgA1 and its corresponding autoantibody, markers of complement activation, and more advanced assays involving MicroRNAs, genomic, and microbiome insights.
講師簡歷	**姓名**：**高治圻** **現職**：Attending Physician, Deputy Director, Department of Internal Medicine, Taipei Medical University Hospital Associate Professor, Department of Internal Medicine, Taipei Medical University **簡歷**： Dr. Kao is a young nephrologist and associate professor at Taipei Medical University, mentored by Professor Mai-Szu Wu. He has published over 60 papers, with his research focusing on the identification of predictive biomarkers for chronic kidney disease (CKD), IgA nephropathy, and related comorbidities, aiming to improve patient care. His representative works include discovering several predictive biomarkers, ranging from genomics, proteomics to metabolomics. Dr. Kao has served as the principal investigator in international clinical trials and has led research projects funded by Taiwan’s Ministry of Science and Technology. Additionally, he is committed to medical education, having spearheaded teaching development projects for internal medicine funded by Taiwan's Ministry of Education. Dr. Kao also actively contributes to public affairs, serving as the executive secretary and member of various committees within the Taiwan Society of Nephrology (TSN). Furthermore, he is deeply engaged in integrative care and geriatric medicine, aiming to enhance the management of elderly patients with kidney-related issues.

課程地點：16 樓胡水旺

主題：從不預期的死到有意義的生~安寧緩和醫療與器官捐贈移植	
課程： **在安寧緩和醫療中實踐器官捐贈的倫理與實務(講題初擬)**	
課程摘要(暫)	本演講探索如何在面對突發性死亡事件時，透過安寧緩和醫療與器官捐贈移植的整合，轉化悲傷為生命延續的力量。透過案例導向學習、角色扮演與模擬練習，學習如何在臨終關懷中引導家屬理解器官捐贈的意義，並協助病人及家屬在尊嚴與愛中完成生命的交接，學習如何在安寧緩和醫療的框架下，引入器官捐贈的概念，實現生命的延續與尊嚴，並在跨專業合作中發揮關懷與專業能力。
講師簡歷	**姓名**：**蔡宏斌** **現職**:臺北市立聯合醫院中興院區整合醫學照護科主任/財團法人器官捐贈移植登錄及病人自主推廣中心執行長 **簡歷**： https://tpech.gov.taipei/News_Content.aspx?n=E64A67F6FCE63AEC&s=A259DD6D7C1CF884

課程地點：16 樓胡水旺

主題：從不預期的死到有意義的生~安寧緩和醫療與器官捐贈移植	
課程： **提升病人末期照護品質與器官捐贈意願(講題初擬)**	
課程摘要	本次演講將深入探討安寧緩和醫療與器官捐贈移植之間的關聯，並強調其在現代醫療體系中的重要性。課程旨在幫助學員理解如何在病人末期階段，透過安寧緩和醫療提供全人照護，並在此過程中促進器官捐贈的意願，實現生命的延續與價值。強調其不僅關注病人的生理需求，更重視心理、社會與靈性的支持。此外，課程將探討器官捐贈的倫理、法律與實務議題，並分析如何在病人末期階段，尊重其自主意願，進行器官捐贈的協調與實施。課程結合安寧緩和醫療與器官捐贈的能力，提升病人末期照護品質，並促進器官捐贈的社會氛圍，實現生命的延續與價值。(暫)
講師簡歷	**姓名**：**鍾孟軒** **現職**：臺北榮民總醫院 移植外科 主治醫師 臺北榮民總醫院 外傷科 主治醫師 臺灣外傷醫學會 副秘書長 **簡歷**： 學歷: 中國醫藥大學 醫學系 經歷: 英國 倫敦國王學院醫院 肝腎移植手術組 觀察員(進修 DCD) 美國 馬里蘭大學/巴爾地摩 休克創傷中心 觀察員 美國 邁阿密器官移植中心 研究學者(進修腹腔多臟器移植) 邁阿密大學/傑克遜紀念醫院 萊德外傷中心 訪問學者 臺北榮民總醫院 外傷病房主任 臺北榮民總醫院 外傷醫學科 研究醫師 臺北榮民總醫院 外科部 一般外科總醫師 臺北榮民總醫院 外科部 住院醫師

課程地點：4 樓誠樸廳

主題：	
課程： **Comprehensive Protection for Heart Failure Patients Across LVEF Spectrum with Jardiance**	
課程摘要	This course focuses on comprehensive protection for patients with heart failure across the full spectrum of left ventricular ejection fraction (LVEF), with a detailed examination of Jardiance (empagliflozin) in treatment. Heart failure is a complex condition characterized by the heart's inability to pump blood effectively, impairing the function of organs throughout the body. Based on LVEF, heart failure can be classified as reduced (HFrEF), preserved (HFpEF), or mid-range (HFmrEF). Jardiance, an SGLT2 inhibitor, has been shown to significantly improve outcomes in HFrEF patients by reducing hospitalization rates and mortality. Importantly, its benefits extend beyond HFrEF; clinical research indicates positive effects in HFpEF and HFmrEF patients as well. The drug works by enhancing cardiac function, reducing fluid retention, and lowering the risk of cardiovascular events, thereby improving the quality of life for heart failure patients. This course will explore Jardiance's mechanisms of action, review clinical trial results, and examine its application across different LVEF categories. It will also address personalized treatment strategies aimed at delivering comprehensive management and enhanced protection for patients with heart failure.
講師簡歷	**姓名**：**徐千彝** **現職**：臺北醫學大學醫學院副教授/附設醫院心臟內科主治醫師暨研究部副主任 **簡歷**： 學歷 2014-2020 國立陽明大學臨床醫學研究所博士 2000-2007 國立陽明大學醫學系學士 經歷 2023.08- 臺北醫學大學醫學系內科學科副教授 2023.09- 臺北醫學大學附設醫院研究部副主任(醫療) 2020.01- 台灣高血壓學會第八屆理事 2016.11- 臺北醫學大學附設醫院專任主治醫師 2020.08-2023.07 臺北醫學大學醫學系內科學科助理教授 2014.08-2020.07 國立陽明大學兼任講師 2014.07-2016.07 臺北榮民總醫院主治醫師

課程地點：4 樓誠樸廳

主題：	
課程： **Empower with Empagliflozin: Unlocking the Superpower in CRM Management**	
課程摘要	This course delves into the transformative potential of empagliflozin, an SGLT2 inhibitor, in managing the interconnected cardio‑ renal‑ metabolic (CRM) syndrome—a triad of type 2 diabetes (T2DM), chronic kidney disease (CKD), and heart failure (HF). Participants will explore the scientific evolution of empagliflozin from a glucose‑ lowering agent to a comprehensive therapeutic tool with multi‑ organ benefits. Landmark clinical trials—EMPA‑ REG OUTCOME, EMPEROR‑ Reduced, EMPEROR‑ Preserved, and EMPA‑ KIDNEY—will be reviewed, demonstrating its consistent ability to reduce cardiovascular death, HF hospitalizations, slow kidney function decline, and improve quality of life.
講師簡歷	**姓名**：**吳忠擇** **現職**：臺北醫學大學醫學系副教授/衛生福利部雙和醫院新陳代謝科主任 **簡歷**： 學歷： 臺北醫學大學臨床醫學研究所博士 國防醫學院醫學系學士 經歷： 衛生福利部雙和醫院新陳代謝科主治醫師 台北醫學大學醫學系新陳代謝學科副教授 前慈濟醫院臺北分院新陳代謝科主治醫師 前三軍總醫院澎湖分院內科部主治醫師 前三軍總醫院新陳代謝科總醫師 前三軍總醫院內科部住院醫師

課程地點：2101 教室

主題：	
課程： **New Metrics in Diabetes Management: TIR, CV%, and CGM in Practice**	
課程摘要	As diabetes management evolves beyond HbA1c, new glycemic metrics such as Time in Range (TIR), Coefficient of Variation (CV%), and Continuous Glucose Monitoring (CGM) have become critical tools for optimizing care. This session will provide an in-depth exploration of how these metrics offer real-time, actionable insights into glucose variability, stability, and overall control. We will discuss the clinical significance of TIR targets, interpretation of CV% as an indicator of glycemic variability, and how CGM data can be integrated into personalized treatment strategies. Case-based examples will illustrate the practical application of these metrics in both type 1 and type 2 diabetes management, including patient education and therapy adjustment. Attendees will gain a clearer understanding of how to incorporate these modern parameters into routine practice to enhance outcomes and patient engagement.
講師簡歷	**姓名**：**林嘉鴻** **現職**：林口長庚營養治療科主任 **簡歷**： 學歷 長庚大學臨床醫學研究所 國立臺灣大學醫學系 經歷 林口長庚醫院內科部住院醫師 林口長庚醫院新陳代謝科研究員 林口長庚醫院新陳代謝科主治醫師

課程地點：2102 教室

主題：	
課程： **The Crucial Role of Timely LDL-C Management in ACS Recovery**	
課程摘要	Current international guidelines (ESC/EAS, ACC/AHA) recommend initiating high‑intensity statins immediately, aiming for at least a 50% LDL‑C reduction and achieving targets below 1.4 mmol/L (55 mg/dL)—or even below 1.0 mmol/L (40 mg/dL) in patients with recurrent events. This course emphasizes the importance of prompt and aggressive LDL‑C (low-density lipoprotein cholesterol) control in patients recovering from acute coronary syndrome (ACS). It begins with the pathophysiological rationale: elevated LDL‑C drives atherosclerosis, making its rapid reduction critical to minimizing recurrent ischemic events.
講師簡歷	**姓名**：**王宇澄** **現職**：亞洲大學附屬醫院內科部主任 (2021-迄今) 亞洲大學附屬醫院心臟科主任(2016-迄今) 教育部定副教授(2022-迄今) 亞洲大學醫學檢驗暨生物技術學系專任副教授(2022-迄今) 中國醫藥大學附設醫院心臟血管系兼任主治醫師(2019-迄今) 中華民國心臟內科專科醫師 (2008-迄今) 中華民國心臟學會心臟內科介入性次專科醫師 (2009-迄今) 中華民國心臟學會專科指導醫師(2015-迄今) 臺灣介入性心臟血管醫學會理事(2022-迄今) 台灣高血壓學會理事(2021-迄今) 台灣心肌梗塞學會理事(2021-迄今) 中華民國血脂及動脈硬化學會監事(2021-迄今) 臺灣介入性心臟血管醫學會編輯暨登錄委員會主委(2022-迄今) 台灣心肌梗塞學會學術委員會主委(2021-迄今) 中華民國心臟學會學術委員會委員(2022-迄今) 中華民國心臟學會治療準則與共識委員會委員(2022-迄今) 臺灣大學智慧健康科技研發中心諮詢委員(2021-迄今) 台中市醫師公會會員代表(2023-迄今) **簡歷**： 學歷 陽明大學醫學系醫學士(1994-2000) 中國醫藥大學臨床醫學研究所博士(2010-2016) 美國德州心臟醫學中心 Texas Heart Institute 研究員 (2011-2012) 經歷 亞洲大學醫學檢驗暨生物技術學系專任助理教授(2016-2022) 教育部定助理教授 (2017-2022)

	亞洲大學附屬醫院內科部副主任 (2018-2021) 中國醫藥大學附設醫院心臟血管系心臟預防醫學科主任 (2015-2019) 台大醫院內科住院醫師 (2003-2006) 台大醫院心臟內科研究醫師 (2006-2008) 中國醫藥大學附設醫院心臟內科主治醫師 (2008-2019) 亞洲大學附屬醫院醫務秘書(2016-2018) 中華民國心臟學會預防醫學委員會委員(2020-2022) 中華民國心臟學會國際交流委員會委員(2018-2022) 台灣介入性心臟血管醫學會副秘書長 (2014-2016) 中華民國心臟學會高血壓委員會委員(2016-2018) 中華民國心臟學會副秘書長 (2018-2020) 中華民國心臟學會甄審委員會委員(2016-2020) 臺灣介入性心臟血管醫學會編輯暨登錄委員會委員(2018-2022) 台灣高血壓學會學術委員會委員(2016-2020)

課程地點：2103 教室

主題：外泌體的臨床應用發展	
課程： **外泌體在心血管疾病的臨床應用**	
課程摘要	Exosomes are small extracellular vesicles (30–150 nm) secreted by a variety of cell types and serve as essential mediators of intercellular communication. Increasing evidence highlights their pivotal roles in the initiation, progression, and resolution of atherosclerosis. These vesicles, derived from endothelial cells, smooth muscle cells, macrophages, and platelets, carry bioactive cargo—including microRNAs (miRNAs), proteins, and lipids—that influence vascular biology and plaque dynamics. Endothelial cell-derived exosomes can maintain vascular homeostasis or contribute to endothelial dysfunction. Macrophage-derived exosomes play dual roles: pro-inflammatory exosomes promote foam cell formation and cytokine release, accelerating plaque development, while anti-inflammatory exosomes support plaque stabilization. Smooth muscle cell-derived exosomes influence vascular calcification, either promoting or inhibiting plaque vulnerability. Platelet-derived exosomes are implicated in coagulation and thrombosis, potentially increasing the risk of plaque rupture. From a therapeutic perspective, engineered exosomes represent a promising platform for targeted drug delivery, aimed at reducing vascular inflammation and enhancing plaque stability. Leveraging the natural capability of exosomes to transfer functional molecules offers a novel and exciting strategy for atherosclerosis treatment. This talk will provide an updated overview of exosomes as key modulators of endothelial function, inflammation, lipid metabolism, and thrombosis in the context of atherosclerosis.
講師簡歷	**姓名**：**張瑋婷** **現職**：Attending physician, Dept. Cardiology, Chi-Mei Medical Center, Tainan, Taiwan Associated Professor, School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan **簡歷**： Wei-Ting Chang received her M.D. and Ph.D. degrees from National Cheng Kung University in Tainan, Taiwan. From 2013 to 2014, she served as a Research Fellow at Harvard Medical School and Brigham and Women's Hospital in Boston, MA, USA. Upon returning to Taiwan, she established the "Circulation Lab" at Chi-Mei Medical Center, Tainan, where she focuses on translational medicine with research interests spanning valvular heart disease, cardio-oncology, and pulmonary hypertension. Dr. Chang has authored more than 150 SCI-indexed publications and was honored with the Ta-You Wu Memorial Award in 2017 for her outstanding research contributions. She currently serves as a cardiologist at Chi-Mei Medical Center and as an Associate Professor at National Sun Yat-sen University in

	Kaohsiung, Taiwan.

課程地點：2103 教室

主題：外泌體的臨床應用發展	
課程： **Exosomes in Chronic Disease: A Clinical Application Overview**	
課程摘要	Exosomes are nanoscale extracellular vesicles (30–150 nm) secreted by virtually all cell types, once considered mere cellular waste but now recognized as critical mediators of intercellular communication. Carrying proteins, lipids, and nucleic acids (mRNA, miRNA, DNA), exosomes reflect the physiological or pathological state of their parental cells and influence recipient cell behavior. Their natural biocompatibility, low immunogenicity, and capacity to traverse biological barriers such as the blood-brain barrier make them highly attractive for clinical use, particularly in chronic disease diagnostics and therapeutics. In diagnostics, exosomes offer a stable, non-invasive liquid biopsy platform. Their lipid bilayer protects their molecular cargo from degradation, allowing for accurate disease detection and monitoring. Specific exosomal miRNAs and proteins have shown diagnostic value in various chronic diseases—cancers (e.g., AR-V7 in prostate cancer), autoimmune disorders (e.g., rheumatoid arthritis), neurodegenerative conditions (e.g., tau and α-synuclein in Alzheimer's and Parkinson's), and cardiovascular diseases. Their presence in accessible fluids such as blood, saliva, and urine enhances patient compliance and enables real-time disease tracking. Therapeutically, exosomes are emerging as promising delivery vehicles for drugs, nucleic acids, and proteins. Their ability to target specific cells, avoid immune clearance, and deliver cargo with high efficiency allows for enhanced treatment of cancers, inflammatory diseases, and neurological disorders. Mesenchymal stem cell (MSC)-derived exosomes, in particular, have demonstrated anti-inflammatory, regenerative, and immunomodulatory properties, making them powerful tools in cell-free therapy. Engineered exosomes can further increase specificity through surface ligand modification and cargo loading via transfection, electroporation, or extrusion. Despite these advantages, several challenges limit clinical translation. Current isolation techniques yield heterogeneous and low-purity exosome populations, and the lack of standardized protocols for characterization and quantification hinders reproducibility and regulatory approval. GMP-compliant large-scale production remains a critical bottleneck. Moreover, understanding exosomal pharmacokinetics, optimal dosing, and long-term safety requires extensive clinical validation. Regulatory frameworks for exosome-based therapies are still evolving, adding to the complexity of clinical adoption. Future directions focus on improving isolation technologies, enhancing targeting capabilities through bioengineering, and integrating AI, nanotechnology, and microfluidics for better design and tracking. The global exosome therapy market is expected to grow significantly, driven by rising chronic disease burdens and the demand for personalized, minimally invasive

	medical solutions. Interdisciplinary collaboration between academia, biotech, and regulatory bodies will be crucial to overcoming current limitations and realizing the full clinical potential of exosomes. In conclusion, exosomes offer transformative potential in chronic disease management as diagnostic biomarkers and therapeutic vehicles. With ongoing advances in standardization, manufacturing, and translational science, exosomes may redefine precision medicine, enabling safer, more targeted, and patient-friendly approaches to treating complex chronic conditions.
講師簡歷	**姓名**：**蕭世欣** **現職**：Director of Cell Therapy Center **簡歷**： KAOHSIUNG MEDICAL UNIVERSITY, Kaohsiung City, Taiwan Sep. 1 st 1989/Jun. 30th 1996 Undergraduate Degree, Bachelor of Medicine PROGRAM IN MOLECULAR MEDICINE, SCHOOL OF LIFE SCIENCES, Sep. 1st 2010/Jun. 28 th 2017 NATIONAL YANG-MING UNIVERSITY, Taipei City, Taiwan Post Graduate Degree, Doctor of Philosophy

臺北醫學會研討會_議程摘要與講師簡歷(暫定)

課程地點：16 樓胡水旺

主題：Future Hospital-1 **特色醫院**	
課程： **Smart Hospital Control Tower for Healthy Longevity**	
課程摘要	Taipei Municipal Gan-Dau Hospital, established in 2000 and managed by Taipei Veterans General Hospital, stands as Taiwan's pioneering lighthouse hospital demonstrating concrete smart technology implementations for population-level healthy longevity. Originally focused on chronic disease management, the hospital has transformed into a comprehensive smart healthcare hub through advanced digital infrastructure and AIoT applications. The hospital's smart control tower capabilities are built upon solid technological foundations: a comprehensive 108-system HIS platform with 95% in-house development, structured relational databases optimized for AI applications, and cloud-based next-generation HIS architecture. Key smart implementations include intelligent bed mattresses equipped with sensors that monitor patient positioning, movement, and vital status in real-time across the 9th floor inpatient ward, providing immediate visual feedback to healthcare teams. Gan-Dau Hospital's iHARP (Healthy Aging & Rejuvenation Platform) integrates wearable devices and health monitoring systems to enable predictive analytics for dementia risk, mortality risk, and chronic disease progression. The hospital has successfully deployed AI-powered diabetic retinopathy detection systems, processing half of all diabetic eye examinations in 2022, alongside plans for generative AI-assisted medical record creation for telemedicine consultations. Additional smart innovations include whole-hospital virtual health insurance card applications designed for older patients, humancentric engineering-based intelligent lighting systems, and many AI-powered diagnostics. The hospital earned the 2023 Digital Transformation Excellence Award, recognizing its systematic approach to healthcare digitalization. The control tower model enables seamless information integration across all patient journey phases, from community health monitoring through care innovations. Gan-Dau Hospital accelerates clinical workflows, reduces workloads, and extends care beyond hospital walls into community settings. For Taiwan's aging population, Gan-Dau Hospital's evidence-based smart control tower approach represents a replicable model for sustainable, technology-enabled healthy longevity management. The hospital's success demonstrates how systematic integration of IoT sensors, AI diagnostics, cloud computing, and predictive analytics can transform traditional chronic care delivery into proactive population health management, serving as a blueprint for

	community hospitals implementing smart healthcare ecosystems nationwide.
講師簡歷	**姓名**：**陳亮恭** **現職**：Superintendent, Taipei Municipal Gan-Dau Hospital (Managed by Taipei Veterans General Hospital) Distinguished Professor & Director, Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University **簡歷**： Professor Chen earned his MD from National Yang-Ming University School of Medicine (1989-1996) and PhD from the Institute of Health Policy and Welfare, expanding his expertise from biomedical research to public policy. After practicing orthopedic surgery at Yuan-Shan Veterans Hospital (1996-1998) and completing family medicine residency at Taipei Veterans General Hospital (1998-2003), he pursued international academic exposure as a Visiting Scholar at Oxford University's Department of Clinical Geratology in 2005. His academic career advanced from lecturer in Family Medicine at National Yang-Ming University (2002) to full professor in Geriatric Medicine (2014). Professor Chen has held pivotal leadership positions, including Director of the Center for Geriatrics and Gerontology at Taipei Veterans General Hospital (2006) and Director of the Aging and Health Research Center at National Yang Ming University (2014, later transformed into the Center for Healthy Longevity and Aging Sciences in 2021). Currently serving as Superintendent of Taipei Municipal Gan-Dau Hospital since 2021, Professor Chen continues to lead groundbreaking research with over 550 international publications in Gerontology and Geriatrics. He actively integrates artificial intelligence in healthy aging research since 2016, collaborating with international computer science leaders. His research leadership includes founding the Asian Working Group for Sarcopenia (2013) and publishing the highly influential Asian Consensus for Sarcopenia Diagnosis (2014, revised 2019), which has gained extensive international attention and promoted research activities across Asian countries. Professor Chen's current global recognition is exceptional - selected as among the world's top 2% scientists by Scopus and Stanford University, ranking first in Clinical Medicine in Taiwan for 5 consecutive years. Today, he remains a key policy influencer across public health, age-friendly services, social welfare, and long-term care in Taiwan. Recent prestigious awards include the 2020 Morley's Award, 2021 National Award of Innovation, 2022 Ding-Ge Award for Digital Transformation and 2025 Distinguished Researcher of National Science and Technology Council. He currently serves as chief editor of Archives of Gerontology and Geriatrics and associate editor of multiple leading journals.

課程地點：16 樓胡水旺

主題：Future Hospital-1 **特色醫院**	
課程： **Building a digital native hospital(講題初擬)**	
課程摘要(暫)	The founding of National Yang Ming Chiao Tung University is to integrate Chiao Tung's strengths in engineering and information technology with Yang Ming's strengths in biomedical research and medicine. We plan the future health care with the applications of cloud service, Artificial Intelligence, Internet of Things and Robotics. The design of a Digital native hospital is based on the idea of TSMC fab that exploits total automation to achieve manufacturing excellence. Big data from multiple sensors facilitate machine learning to develop algorithms that enable smart diagnosis engine and precision yield. A digital twin of our building (Building Information Modeling) served as a digitized platform for our hospital that integrates real-time locating systems and sensors for every person, equipment and utilities. The automatic transport system enables the right supply for the right patient every time automatically. A dynamic digital replica of each patient, created with personal health record, imaging, laboratory and omics data that continuously interact with the physiological data derived from wearable sensors will create a digital twin simulates the real-world patients to model each treatment plan and prognosis. Medical care is not only managing diseases but to maintain health at everywhere continuously. Digitalization is transforming our health care practice, from Empirical to Precision Medicine, from population constructed evidenced based medicine to personalized treatments.(暫)
講師簡歷	**姓名**：**洪大川** **現職**：部定助理教授/馬偕紀念醫院總院副院長暨淡水馬偕醫院院長 **簡歷**： 學歷 中國醫藥大學中醫學系醫學士 國立台灣大學管理學院商學碩士 經歷 新北市醫師公會理事 中華民國心臟學會理事暨財務委員會副主委 台灣介入性心臟血管醫學會理事暨公共醫療政策委員會主委

課程地點：4 樓誠樸廳

主題：Post-ACS (PAC) 共識計畫研討	
課程： **共識計畫緣起與發展目標簡介-抗血小板藥物**	
課程摘要	在抗血小板治療發展過程中，面對血栓與出血風險的平衡需求，學界與臨床專家群成立共識計畫，以期為臨床提供明確指引與實務策略。本課程旨在透過共識計畫內容與最新臨床指南，協助臨床人員理解抗血小板藥物應用之原理與實務決策，提升治療安全性與患者預後。 發展目標如下：建立基於風險評估（血栓 vs 出血）的治療分層框架，並提出治療強度與療程長度的調整規範，推動個人化治療，包括使用更精準的 $P2Y_{12}$抑制劑（如 ticagrelor、prasugrel）與定期評估出血風險（如 PRECISE-DAPT、ARC-HBR）、提供醫師調整 DAPT 時機的合適依據，協助制定後續單一抗血小板療法（如降至 aspirin 或 $P2Y_{12}$抑制劑）策略，減少長期副作用。
講師簡歷	**姓名**：**王宇澄** **現職**：亞洲大學附屬醫院內科部主任 (2021-迄今) 亞洲大學附屬醫院心臟科主任(2016-迄今) 教育部定副教授(2022-迄今) 亞洲大學醫學檢驗暨生物技術學系專任副教授(2022-迄今) 中國醫藥大學附設醫院心臟血管系兼任主治醫師(2019-迄今) 中華民國心臟內科專科醫師 (2008-迄今) 中華民國心臟學會心臟內科介入性次專科醫師 (2009-迄今) 中華民國心臟學會專科指導醫師(2015-迄今) 臺灣介入性心臟血管醫學會理事(2022-迄今) 台灣高血壓學會理事(2021-迄今) 台灣心肌梗塞學會理事(2021-迄今) 中華民國血脂及動脈硬化學會監事(2021-迄今) 臺灣介入性心臟血管醫學會編輯暨登錄委員會主委(2022-迄今) 台灣心肌梗塞學會學術委員會主委(2021-迄今) 中華民國心臟學會學術委員會委員(2022-迄今) 中華民國心臟學會治療準則與共識委員會委員(2022-迄今) 臺灣大學智慧健康科技研發中心諮詢委員(2021-迄今) 台中市醫師公會會員代表(2023-迄今) **簡歷**： 學歷 陽明大學醫學系醫學士(1994-2000) 中國醫藥大學臨床醫學研究所博士(2010-2016) 美國德州心臟醫學中心 Texas Heart Institute 研究員 (2011-2012) 經歷 亞洲大學醫學檢驗暨生物技術學系專任助理教授(2016-2022)

	教育部定助理教授 (2017-2022) 亞洲大學附屬醫院內科部副主任 (2018-2021) 中國醫藥大學附設醫院心臟血管系心臟預防醫學科主任 (2015-2019) 台大醫院內科住院醫師 (2003-2006) 台大醫院心臟內科研究醫師 (2006-2008) 中國醫藥大學附設醫院心臟內科主治醫師 (2008-2019) 亞洲大學附屬醫院醫務秘書(2016-2018) 中華民國心臟學會預防醫學委員會委員(2020-2022) 中華民國心臟學會國際交流委員會委員(2018-2022) 台灣介入性心臟血管醫學會副秘書長 (2014-2016) 中華民國心臟學會高血壓委員會委員(2016-2018) 中華民國心臟學會副秘書長 (2018-2020) 中華民國心臟學會甄審委員會委員(2016-2020) 臺灣介入性心臟血管醫學會編輯暨登錄委員會委員(2018-2022) 台灣高血壓學會學術委員會委員(2016-2020)

課程地點：4 樓誠樸廳

主題：Post-ACS (PAC) 共識計畫研討	
課程： **運用智慧醫療工具改善心臟疾病病人照護結果**	
課程摘要	在急性冠心症（ACS）後，根據最新共識，建議於住院期間即啟動高強度 statin 治療，並視風險考量合併 ezetimibe 或 PCSK9 抑制劑，以迅速達成 LDL-C 目標＜55 mg/dL。出院後建議於 4 至 8 週內追蹤血脂並調整治療。為提升達標率，應採用多元策略，包括數位提醒、藥師介入與固定劑量合併療法等，以克服臨床實務中的落差。本場演講將整合國內外最新實證與實務經驗，深入解析 PAC 共識計畫如何落地執行，協助第一線醫師提升病人血脂控制率、縮短治療延遲。
講師簡歷	**姓名**：**陳志維** **現職**：臺北醫學大學附設醫院心臟內科主治醫師暨健康管理中心副主任 **簡歷**： 學歷 2004-2011 中山學醫學大學醫學士 經歷 2024.03- 臺北醫學大學附設醫院健康管理中心副主任 臺北醫學大學附設醫院住院醫師、主治醫師 2022.08- 臺北醫學大學醫學系內科學科講師 2012.08-2013.07 臺北榮民總醫院住院醫師

課程地點：4 樓誠樸廳

主題：Post-ACS (PAC) 共識計畫研討	
課程： **心肌梗塞後預防心衰竭之治療策略**	
課程摘要	心肌梗塞後心衰竭是常見且具預後不良的併發症，透過多層次干預可以有效預防與管理。本次演講從急性處置到長期照護，整合藥物、生活與追蹤策略，旨在協助臨床人員系統化預防心肌梗塞後之心衰竭，提高患者長期存活與生活品質。 早期進行心肌再灌注——如急性冠脈介入術（PCI）或溶栓處理——能有效限制心肌壞死範圍，以降低重塑及後續心衰發展的機會。近來，SGLT‑2 抑制劑（如 empagliflozin）已納入心衰心肌梗塞後的標準治療中，不僅於慢性心衰病例有益，在急性梗塞病人中亦開始顯示抗重塑效果，甚至可減少 NT‑proBNP 水準與再住院風險。綜觀而言，預防心衰竭的策略應從急性處置的快速再灌注、神經激素系統抑制，到新興 SGLT‑2 治療，以及生活方式與長期監控，形成一體化連續照護模式，保障心肌梗塞患者的長期心臟健康。
講師簡歷	**姓名**：**徐千舜** **現職**：臺北醫學大學醫學院副教授/附設醫院心臟內科主治醫師暨研究部副主任 **簡歷**： 學歷 2014-2020 國立陽明大學臨床醫學研究所博士 2000-2007 國立陽明大學醫學系學士 經歷 2023.08- 臺北醫學大學醫學系內科學科副教授 2023.09- 臺北醫學大學附設醫院研究部副主任(醫療) 2020.01- 台灣高血壓學會第八屆理事 2016.11- 臺北醫學大學附設醫院專任主治醫師 2020.08-2023.07 臺北醫學大學醫學系內科學科助理教授 2014.08-2020.07 國立陽明大學兼任講師 2014.07-2016.07 臺北榮民總醫院主治醫師

課程地點：2101 教室

主題：泌尿疾患治療新進展	
課程： **泌尿系統疾病治療的嶄新篇章：從傳統手術到智慧醫療(講題初擬)**	
課程摘要(暫)	泌尿系統疾病的治療正經歷一場深層轉型，從傳統開放手術到內視鏡、腹腔鏡及機器人手術的演進，大幅提升了臨床療效與患者預後。近年來，智慧醫療技術——包括人工智慧輔助影像診斷、術前規劃演算法、機器人自動控制、以及整合式病人監測系統——已逐步導入泌尿臨床決策與治療流程中。再者，個人化醫療策略、基因定序與生物標誌物在泌尿腫瘤與功能性疾病管理中也展現潛力。本演講將系統性回顧這些新興技術在泌尿科的臨床應用現況與實證成效，並探討其對外科決策流程、醫病關係與醫療資源配置所帶來的挑戰與契機。透過多維度的討論，勾勒出泌尿疾病治療邁向智慧整合時代的發展藍圖。
講師簡歷	**姓名**：**林登龍** **現職**：臺北榮民總醫院泌尿部 特約主治醫師 **簡歷**： 學歷 台北醫學院畢 國立陽明大學醫學博士 經歷 美國賓州大學泌尿外科研究員 臺北榮民總醫院 泌尿部 部主任 臺北榮民總醫院泌尿外科主治醫師 國立陽明大學 教授

課程地點：2101 教室

主題：泌尿疾患治療新進展	
課程： **微創與聚焦治療在良性前列腺增生（BPH）中的應用與未來趨勢(講題初擬)**	
課程摘要(暫)	本次演講將透過各類微創與聚焦治療技術的適應症、優勢與限制，掌握最新臨床研究成果與技術應用，進一步衡量其成本效益與患者價值，並探討 AI 與 3D 列印在泌尿手術與影像診斷的實務整合，展望未來發展趨勢。針對前列腺增生（BPH），新型微創技術如水蒸氣熱療（Rezum）、水射流消融（Aquablation）及支撐性尿道植入術（UroLift/iTIND）皆已完成多中心臨床驗證，實現門診局麻操作並有效改善症狀，同時保留性功能與減少恢復時間，在泌尿結石治療方面，靈活式輸尿管鏡結合雷射碎石術（RIRS）已成為常規方法，而全球最新發展如印度 AIIMS 利用 3D 列印患者專屬腎臟模型進行 PCNL，提升手術精準度與安全性，並針對膀胱頸梗阻與下尿路症狀，水蒸氣療法與支撐植入同樣提供低複發率與即時緩解的優勢。
講師簡歷	**姓名**：**楊晨光** **現職**：臺中榮民總醫院泌尿醫學部泌尿腫瘤科科主任 **簡歷**： 學歷 中山醫學大學畢業 經歷 經歷： 臺中榮民總醫院 外科部 泌尿外科 主治醫師 臺中榮民總醫院 外科部 總醫師 臺中榮民總醫院 外科部 住院醫師

課程地點：2101 教室

主題：泌尿疾患治療新進展	
課程： **Prostate cancer focal treatment**	
課程摘要	Prostate cancer is one of the most common cancers in men, and its treatment strategy depends on the tumor's stage, grade, and the patient's overall health status. Localized therapy primarily focuses on controlling the tumor locally, with common methods including surgery, radiation therapy, and emerging non-invasive techniques. This lecture aims to help participants understand the staging and grading systems for prostate cancer, master the indications, advantages, drawbacks, and clinical applications of various local treatment options, and explore the development trends and future prospects of emerging therapeutic technologies.
講師簡歷	**姓名**：**周安琪** **現職**：臺北醫學大學附設醫院泌尿科主治醫師 **簡歷**： 學歷 臺北醫學大學醫學士 經歷 泌專醫字第 001233 號 臺北醫學大學附設醫院泌尿科主治醫師 臺北醫學大學附設醫院卓越攝護腺中心成員 泌尿科專科醫師 台灣泌尿學會會員 臺北醫學大學附設醫院泌尿科總住院醫師 林口長庚醫院一般科住院醫師 新加坡國立大學實習醫師

課程地點：2101 教室

主題：泌尿疾患治療新進展	
課程： **Clinical Study to Evaluate the Efficacy of the Lite-Med LM-IASO Device for the Treatment of Urge Urinary Incontinence (UUI) in Women(講題初擬)**	
課程摘要(暫)	This course presents a clinical study evaluating the efficacy of the Lite-Med LM-IASO device in treating urge urinary incontinence (UUI) in women. The LM-IASO device utilizes Low-Intensity Extracorporeal Shock Wave Therapy (LiESWT), a non-invasive treatment that has shown promise in improving bladder function and reducing UUI symptoms. The study design is a prospective, randomized, single-blind, multicenter trial involving female participants diagnosed with UUI. Participants are assigned to either the treatment group, receiving LiESWT via the LM-IASO device, or a control group. The primary outcome measure is the change in the mean number of daily UUI episodes from baseline to 12 weeks. Secondary outcomes include changes in bladder diaries, quality of life assessments, and patient-reported outcomes. The course will delve into the mechanisms of LiESWT, the study methodology, data analysis, and the clinical implications of these findings. Participants will gain insights into the potential applications of LiESWT in urological practice and its role in advancing non-invasive treatments for UUI.
講師簡歷	**姓名**：**林桂亭** **現職**：美國加州大學教授 **簡歷**： Education MD, 1986, Weifang Medical College, Shandong, China, Medicine MS, 1991, Harbin Medical University, Harbin, China, Surgery PhD, 2001, Peking University, Beijing, China, Surgery (Urology) Biography Guiting Lin, MD, PhD received his medical degree at the Weifang Medical College in Shandong, China. Lin trained in Surgery at the Harbin Medical University in Harbin China and specialized in Urologic Surgery at Peking University, China's premier medical school located in Beijing. In 2001, Lin joined the Department of Urology as a Postdoctoral Research Fellow. He was promoted to Assistant Researcher in 2005, to Assistant Professor in 2007, to Associate Professor in 2010, and to Professor in 2010. In China Lin received numerous awards from the Shandong Ministry of Health, and Peking University. His UCSF research has also received recognition, including the 2002 Outstanding Young Researcher award and 2016 ISSM Zorgniotti-Newman Prize given by the International Society for Sexual and Impotence Research. Lin conducts research in the Urology Laboratory and has authored or co-authored over 140 publications.

課程地點：2102 教室

主題：腦刺激

課程： **The New Development of rTMS**	
課程摘要	repetitive Transcranial Magnetic Stimulation (rTMS), as. a non-invasive brain stimulation technique, has been widely utilized in the management of various psychiatric and neurological conditions, including depression, anxiety disorders, obsessive-compulsive disorder, chronic pain and stroke rehabilitation. In this presentation, the new development of rTMS will be introduced regarding to augmentation with medication and optimization of parameter.
講師簡歷	**姓名**：**Joshua C. Brown** **現職**：Assistant Professor, Harvard Medical School, Boston, MA, USA Attending Psychiatrist at McLean Hospital, Belmont, MA **簡歷**： Biography Joshua C. Brown, MD, PhD, is a psychiatrist, neurologist, and neuroscientist. He is medical director of the Transcranial Magnetic Stimulation (TMS) Service and director of TMS research in the Division of Depression and Anxiety Disorders at McLean Hospital. Dr. Brown is also director of the Brain Stimulation Mechanisms Laboratory at McLean and an assistant professor of Psychiatry at Harvard Medical School. Dr. Brown is internationally recognized for his work on the synaptic mechanisms of TMS, pharmacologic augmentation of TMS, and TMS parameter selection. He is the founding editor-in-chief of the new journal, Transcranial Magnetic Stimulation, and is the president-elect of the Clinical TMS Society.

課程地點：2102 教室

主題：腦刺激	
課程： **TMS Development in the United States**	
課程摘要	Transcranial Magnetic Stimulation (TMS) has undergone a remarkable transformation since its introduction to the United States. Initially cleared by the FDA in 2008 for treatment-resistant depression, TMS has since evolved into a widely accepted neuromodulation modality with expanding clinical indications, technological innovations, and growing insurance coverage. This presentation will trace the development of TMS in the U.S., exploring the rapid growth of the TMS market and proliferation of FDA-cleared devices. We will review the broadening of clinical applications beyond major depressive disorder, the expansion of insurance coverage, and the evolution of TMS treatment protocols. Despite significant progress, key clinical questions remain about patient selection, targeting methods, stimulation protocols, rescue and maintenance TMS, and integration with other treatment modalities. Additionally, current challenges such as equitable access, provider training, treatment standardization, and insurance coverage gaps will be discussed alongside future directions in research and clinical practice. Attendees will gain a comprehensive understanding of how TMS has evolved in the U.S. and ideas about future directions in the field.
講師簡歷	**姓名**：**Martha Koo** **現職**：Chief Medical Officer, Your Behavioral Health, USA President, Clinical Transcranial Magnetic Stimulation Society **簡歷**： A pioneer in the development and application of Transcranial Magnetic Stimulation (TMS), Dr. Koo opened the South Bay TMS Therapy Center in 2009, and she was a founding member of the Clinical TMS Society (CTMSS). She currently serves on the CTMSS Board of Directors and the Executive Council as VP-President Elect. Dr. Koo completed undergraduate studies at Princeton University and medical training at the UCLA David Geffen School of Medicine. She obtained psychiatry residency training at the UCLA Resnick Neuropsychiatric Institute and subsequent psychoanalytic training at the New Center for Psychoanalysis. Dr. Koo is Board Certified in Psychiatry and in Addiction Medicine. The South Bay TMS Center evolved into the Neuro Wellness Spa, where Dr. Koo is Founding CEO. Neuro Wellness Spa is an in-network psychiatry practice with six outpatient clinics across the greater LA area that offer medication management, TMS and ketamine therapy. Additionally, Dr. Koo is the Medical Director at Clear Recovery Center, which provides the full continuum of in-network behavioral health treatment— from detox, dual diagnosis and mental health residential

	programs to outpatient treatment (PHP, IOP & OP) for teens and adults. Dr. Koo is the author of several peer-reviewed articles on the application and efficacy of TMS. Dr. Koo is a distinguished Fellow of the CTMSS and the American Psychiatric Association. With a strong background in human psychodynamics, psychological theory, psychiatric medicine, and neuroscience, Dr. Koo has dedicated her career to community, academic and professional advocacy for the advancement of psychiatric treatment and to increase access and awareness to the most effective, personalized mental health interventions.

課程地點：2102 教室

主題：腦刺激	
課程： **TMS Development in Australia**	
課程摘要	Australia has played a pioneering role in the scientific and clinical development of TMS, with early contributions including one of the first clinical applications in depression (Pridmore, 1999), an early randomised controlled trial (Fitzgerald et al., 2003), and the world's first trial of accelerated TMS protocols (Loo et al., 2007). This presentation will chart the trajectory of TMS research and clinical translation in Australia, highlighting how sustained research efforts in rigorous clinical trials and translational neuroscience has shaped international practice. Drawing on examples from the presenter's own lab and international collaborations, the presentation will explore cutting edge innovations such as accelerated protocols, pharmacological augmentation and expansion to indications beyond depression by targeting neuroimaging-derived brain networks. It will also reflect on Australia's leadership in TMS education and contributions to training standards and implementing evidence-based guidance, positioning TMS as a platform technology capable of transforming mental health care beyond depression alone.
講師簡歷	**姓名**：**Leo Chen** **現職**：Head, Brain Stimulation Lab, Department of Psychiatry, the University of Melbourne, Australia Academic Psychiatry Lead, St Vincent's Hospital Melbourne, Australia Associate Professor and Consultant Psychiatrist, the University of Melbourne and St Vincent's Hospital Melbourne, Australia **簡歷**： Leo Chen is a Melbourne-based psychiatrist and neuroscientist who recently assumed the role of Associate Professor in the Department of Psychiatry at the University of Melbourne and Psychiatry Research Lead at St Vincent's Hospital Melbourne, where he heads the Brain Stimulation Lab. He has led multiple brain stimulation trials, and was author on international consensus statements defining the brain stimulation subspecialty, its training standards, as well as clinical practice guidelines.

課程地點：2103 教室

主題：整合醫學照護：從醫院到居家 HAH	
課程： **整合照護新面貌: AI 智慧科技和遠距醫療的進展**	
課程摘要	AI 智慧科技與遠距醫療為整合照護的重要支柱，本課程由理論、技術工具、制度政策與在地實作案例構成，本次演講在培育具備 AI 與遠距整合能力的照護專業者，實踐從醫院延伸至社區與家庭的無縫整合照護新模式。內容包含探討 AI 在診斷影像、呼吸與生理訊號偵測等領域的應用，如何提升篩檢效率與精準度 、5G 與智慧居家照護整合，並探究智慧行動醫護平台、人臉辨識／熱成像等技術在院內安全與流程優化之優勢，再由實務課程延伸討論政策與倫理議題。
講師簡歷	**姓名**：**蔡岡廷** **現職**：部定助理教授/奇美醫院家庭醫學部部長 **簡歷**： 學歷 高雄醫學大學醫學系學士 成功大學臨床醫學研究所所碩士 經歷 奇美醫院家庭醫學部住院醫師、總醫師、主治醫師 台大醫學院附設醫院老年醫學部研究員 奇美醫院全人醫療科主任 奇美醫院整合醫療中心主任 長榮大學醫學研究所兼任助理教授 南台科技大學高齡福祉服務系兼任助理教授

課程地點：2103 教室

主題：整合醫學照護：從醫院到居家 HAH	
課程： **老有所安: 預立醫療決定與在宅統合照護之新進展**	
課程摘要	高齡社會下，「老有所安」不僅是理念，更是醫療與照護的務實策略。本次演講結合理論、政策、實務案例與策略工具，目的在培育能推動「預立醫療決定＋在宅統合照護」的專業人才，共同實現安心老年的醫療照護願景。 本次聚焦在預立醫療決定(AD)與諮商(ACP)及在宅統合照護實務進展，建立「醫院－社區－居家」整合網絡，發展在宅急症照護與居家安寧服務，探討 ACP 與在宅照護在推廣面臨的文化阻力、跨領域協作、法規與財務機制，以及如何訓練醫療、社工與社區人員成為行動核心推手。
講師簡歷	**姓名**：**蔡宏斌** **現職**：臺北市立聯合醫院中興院區整合醫學照護科主任/財團法人器官捐贈移植登錄及病人自主推廣中心執行長 **簡歷**： https://tpech.gov.taipei/News_Content.aspx?n=E64A67F6FCE63AEC&s=A259DD6D7C1CF884

課程地點：2103 教室

主題：整合醫學照護：從醫院到居家 HAH	
課程： **Emergency Care Beyond the Hospital: Building a Community-Based Safety Net for Acute Home Care**	
課程摘要	As Taiwan enters a super-aged society, traditional hospital-based care systems face rising pressure from emergency crowding and inpatient shortages. In response, Wan Fang Hospital has developed an acute Hospital-at-Home (HaH) model rooted in emergency medicine. This model allows eligible patients to receive hospital-level care at home through coordinated services including physician-led teleconsultations, bedside diagnostics (POCT, POCUS), and structured follow-ups. This presentation shares the operational design of Wan Fang's HaH model, including patient selection, case manager handoffs, and integration with a regional “satellite medical network” serving districts like 文山 and 深坑. Case examples highlight challenges in antibiotic access, remote care, and cross-institution collaboration. The vision is to establish a resilient, scalable acute care network that extends beyond hospital walls—bridging emergency services, primary care, and long-term care into a cohesive ecosystem.
講師簡歷	**姓名**：**楊智皓** **現職**：Emergency Physician, Deputy Director, Department of Community Medicine, Wan Fang Hospital, Taipei Medical University **簡歷**： Dr. Chih-Hao Yang is an emergency physician and the deputy director of community medicine at Wan Fang Hospital. He has led the implementation of acute Hospital-at-Home (HaH) services, extending admission-level care into patients’ homes. His work focuses on building regional satellite care networks that integrate hospital, community clinics, and long-term care providers to create an effective safety net for frail or mobility-limited patients. Dr. Yang actively collaborates across disciplines and has spearheaded efforts in clinical process design, remote monitoring integration, and community-based antibiotic protocols for pneumonia and soft tissue infections.

課程地點：2104 教室

主題：人工智慧在臨床試驗應用的最新趨勢與倫理議題	
課程： **AI 臨床試驗及實務考量**	
課程摘要	大數據和人工智慧（AI）在居家醫療中的應用正逐漸成為現代醫療保健的重要組成部分。本次演講將探討這兩項技術在居家醫療中的應用，以及引發的主要倫理議題。 1. 應用前景: 健康監測與預警、遠程醫療、輔助診斷與治療決策、慢性病管理。 2. 倫理議題: 隱私與數據安全、公平性與非歧視性、透明性與可解釋性、責任與問責。 希望能夠為醫療領域提供更為全面和深刻的見解，推動大數據和 AI 技術在居家醫療中的健康發展。
講師簡歷	**姓名**：**陳育群** **現職**：臺北榮民總醫院玉里分院副院長 **簡歷**： 台北榮總玉里分院副院長 國立陽明大學醫學院/生命科學院生物醫學資訊研究所合聘副教授 國立陽明大學附設醫院教學研究部部主任 國立陽明大學附設醫院教學研究部主治醫師 台北榮民總醫院住院醫師

課程地點：2104 教室

主題：人工智慧在臨床試驗應用的最新趨勢與倫理議題	
課程： **AI 臨床試驗及法律考量**	
課程摘要	醫師於利用 AI 協助提供照護時可採取之步驟，以履行其倫理與專業職責，期能藉此降低對患者造成傷害之風險；本指引之特色在於，其要求醫師為 AI 之利用結果負最終之責任。
講師簡歷	**姓名**：**邱文聰** **現職**：中央研究院智財技轉處處長 **簡歷**： 中央研究院法律學研究所研究員

課程地點：2203 教室

主題：Advance in Neuroscience
神經醫學新進展

課程：
AIOT 驅動的遠距心電腦波同步監測系統設計與應用

課程摘要	心電圖（Electrocardiography, ECG）與腦電圖（Electroencephalography, EEG）是評估心臟功能與大腦神經活動的非侵入式生理量測工具。但由於傳統儀器體積龐大、價格昂貴且大多設置在醫療院所受限於人力資源，對於臨床上普及造成一定的困難。隨著科技進步，物聯網（Internet of Things, IoT）飛速發展，透過無線傳輸與網路儲存架構，可支援生理訊號的連續監測與雲端分析，不僅能降低照護人員的負擔，也有助於提升效率、改善醫療品質，但如何整合人工智慧（Artificial Intelligence, AI）和 IoT 技術，建置同步監控、訊號分析與雲端資料處理能力的系統，成為推動智慧醫療應用的關鍵挑戰與發展趨勢。 本 IoT 系統搭配感測器、演算法、軟硬體、物聯網以及臨床介入服務實現資訊和實體的整合。本團隊開發的微型腦波心電儀具備低功耗與長時間監測能力，訊號經由微控制器進行前處理與數位轉換後，透過藍牙模組傳輸至傳輸盒，再經由 Wi-Fi 或 4G 行動網路上傳至雲端伺服器進行儲存與分析，演算法上透過不同生理訊號頻譜分析技術與功率指標計算，提供量化數據。後端架構支援結構化資料庫管理與遠距監控介面，視覺呈現各項生理指標變化，協助醫護人員快速掌握患者狀態進行診斷與決策。 本系統也於精神專科醫院做應用，對居家或住院患者進行長時間的連續監測，探討自律神經、睡眠品質、活動量分析與心腦互動之觀察。系統所建立的生理訊號資料庫可為後續 AI 模型訓練、異常偵測演算法開發與個人化健康預測分析提供重要數據基礎。 未來可進一步擴展至居家照護、亞健康族群監測或是遠距病情追蹤等場景，搭配傳輸盒與雲端平台整合，建立即時回饋、個人化建議與預警的全方位健康管理系統，實現 AIoT 技術在智慧醫療領域的產業化應用與永續發展。
講師簡歷	**姓名**：**郭博昭** **現職**：國立陽明交通大學腦科學研究所教授 **簡歷**： 現職 2006/02- 迄今 教授 國立陽明交通大學 腦科學研究所 2022/07- 迄今 主任 衛生福利部草屯療養院 心腦研究中心 經歷 2006/02- 迄今 教授 國立陽明交通大學 腦科學研究所 2020/12-2022/06 主任 衛生福利部桃園療養院 臨床研究中心 2019/03-2020/11 主任 國立陽明大學 數位醫學中心 2019/02-2020/04 策略副院長 國立陽明大學 醫學院 2017/01-2019/12 臨床研究諮詢顧問 三軍總醫院北投分院 2018/02-2019/01 副院長 臺北醫學大學 醫學科技學院

課程地點：2203 教室

主題：Advance in Neuroscience **神經醫學新進展**	
課程： **從腦波到意識:任務導向 EEG 在神經科學中的創性應用**	
課程摘要	隨著對意識障礙的評估越來越重視行為以外的客觀指標，任務導向 EEG（task‐based EEG）已成為探索「隱性意識」（covert consciousness）的重要工具。在傳統臨床運動反應評估中，約有 40% 的患者可能被誤診為植物狀態，任務導向 paradigms 卻能透過「命令追隨」（command following）活動揭示仍存的意識能力。本次演講將解構這些實驗設計：如何引導受試者進行心理意象（如想像握拳或計數），並透過時間分析 EEG 反應（如 event‐related beta desynchronization）來判斷命令追隨成效，目的在推動 EEG 任務導向技術從研究走向臨床應用，讓「腦波回應」成為理解意識的新窗口。
講師簡歷	**姓名**：**林明錦** **現職**：萬芳醫院專案副院長／ 萬芳醫院神經外科專任主治醫師／ 雙和醫院神經外科兼任主治醫師／ 臺北醫學大學醫學資訊研究所副教授 **簡歷**： 學歷 美國猶他大學生物醫學資訊博士／ 臺北醫學大學醫學資訊研究所碩士／ 臺北醫學大學醫學系學士 經歷 亞太醫學資訊協會秘書長／ 雙和醫院骨鬆肌少衰弱症中心主任／ 雙和醫院神經外科 AI 機器人手術專科主任／ 台灣醫學資訊學會理事長／ 雙和醫院神經外科專任主治醫師

課程地點：16 樓胡水旺

主題：Future Hospital-2 **智慧醫院**	
課程： **MAC WARD:An Innovative Negative-pressure Isolation Ward**	
課程摘要	During the COVID19 pandemic, there was an overwhelming demand for negative-pressure isolation ward. At the start of the pandemic in 2020, the Center For Innovation(CFI) at FJCUH collaborated with TDRI and Miniwiz to create MAC WARD(M:Modular, A:Adaptable, C: Convertible), by utilizing upcycled hospital-grade materials, nano-coated with recycled aluminum materials. Through CATIA, coupled with LCA, BIM and CAD/CAM Digital Technologies, the real-size MAC WARD prototype was built within one month. The modularity allowed MAC WARD to adapt to any space, converting normal patient wards into negative-pressure isolation wards. Moreover, it can be easily dissembled and transported, and the materials can be reused repeatedly. Indeed MAC WARD revolutionized hospital ward, redefined responses to future pandemic, reset how hospital ward is perceived. MAC WARD at FJCUH started receiving patients in June 2021; by December 31, 2022, it has received over 3,000 patients, including those with severe case COVID-19. Six ICU MAC WARD incorporated smart medical technologies, enabling doctors and nurses to monitor patients and operate respirators from a distance, greatly reducing physical contacts and viral transmission. MAC WARD received numerous accolades and media attention, including iF Design Award 2021, 2021 Good Design Award in Japan, and CNN coverage.
講師簡歷	**姓名**：**江清泉** **現職**：Vice President　Fu Jen Catholic University Hospital Chair Professor　Fu Jen Catholic University Professor Emeritus　National Taiwan University Distinguished Visiting Chair　Academia Sinica **簡歷**：　2008-2010　The president of Taiwan Orthopedic Association 2004-2018　Professor, Institute of Business Administration, National Taiwan University 2005-2010　Chairman, Orthopaedic Surgery, Medical College, National Taiwan University 2005-2010　Chairman, Department of Orthopaedic Surgery, National Taiwan University Hospital 2011-2014　Consultant, Ministry of Education, Taiwan 2014-2015　Coach, NTU SPARK 2017-now　Professor Emeritus , National Taiwan University 2017-now　Chair Professor , Fu Jen Catholic University

	2017-now Deputy Superintendent , Fu Jen Catholic University Hospital

課程地點：16 樓胡水旺

主題：Future Hospital-2 智慧醫院	
課程： **Implantation of Artificial Intelligence in Healthcare in KMUH**	
課程摘要	Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) is leading the transformation of Taiwan's healthcare ecosystem through a comprehensive integration of smart healthcare services. The hospital has built a patient-centered, AI-enabled digital care platform that spans outpatient, inpatient, emergency, diagnostic, and administrative workflows—winning national and international recognition for innovation and quality. (1) Integrated Smart Healthcare Blueprint and Digital Transformation • KMUH's smart transformation strategy includes the development of a system-wide digital care architecture supported by a high-performance computing center, talent cultivation programs, and AI research collaborations. The hospital has implemented the "KMUH Smart Dashboard" to monitor operational performance across all care units. (2) AI-Powered Clinical Workflows and Patient Safety • Smart ICU and Decision Support: AI-driven clinical tools are deployed in ICUs to predict patient deterioration and support early intervention. • Generative AI for Nursing Documentation: KMUH's generative AI system has significantly reduced documentation time, allowing nurses to focus on direct patient care while enhancing the quality of records. • Surgical Safety and Anesthesia Systems: A closed-loop system for surgical medication and real-time integration of anesthesia data ensures patient safety and process integrity. (3) Continuity of Care and Telemedicine Innovation • KMUH pioneered Taiwan's first AI-assisted 5G telemedicine program in remote regions, offering real-time ENT, dermatology, and ophthalmology consultations. This effort bridges the healthcare access gap and promotes health equity. (4) Administrative and Diagnostic Service Optimization • AI-enhanced Outpatient Flow: KMUH utilizes big data to predict patient arrival and wait times, creating a seamless outpatient experience. • Closed-loop Diagnostic & Lab Systems: Automation and digitalization across labs and imaging services improve accuracy, timeliness, and traceability. • Smart Pharmacy and Drug Safety: Systems such as ADCs and PRN prescription checks prevent medication errors and streamline pharmacy operations. (5) Sustainable Healthcare and ESG Commitment • KMUH's ESG strategy includes energy-efficient infrastructure, digital governance, and health equity programs, aligning healthcare innovation with sustainability. The hospital's

	achievements have been recognized by the NHQA and other national awards for excellence in smart healthcare. Conclusion: KMUH demonstrates that integrated smart healthcare is not only a technological leap but a strategic transformation for achieving safer, more efficient, and patient-centered care. Through digital innovation, AI deployment, and systemic service design, KMUH is building a replicable and scalable model for sustainable smart healthcare in Asia and beyond.
講師簡歷	**姓名**：**林宗憲** **現職**：高雄醫學大學附設中和紀念醫院副院長 高雄醫學大學附設中和紀念醫院運營管理部主任 高雄醫學大學附設中和紀念醫院心臟血管主治醫師 高雄醫學大學醫學系教授 高雄醫學大學臨床醫學研究所合聘教授 **簡歷**： 高雄醫學大學附設中和紀念醫院內科住院醫師 高雄醫學大學附設中和紀念醫院心臟內科總住院醫師 高雄醫學大學附設中和紀念醫院心導管室主任 高雄醫學大學附設中和紀念醫院心臟血管內科加護病房主任 高雄醫學大學附設中和紀念醫院心功能室主任 高雄醫學大學附設中和紀念醫院行政管理中心主任 高雄醫學大學附設中和紀念醫院心臟血管內科主任 高雄醫學大學附設中和紀念醫院院長室醫務秘書 高雄醫學大學附設中和紀念醫院醫品病安管理中心主任 高雄醫學大學教師發展中心臨床技能組組長

課程地點：4 樓誠樸廳

主題：健康風險預測	
課程： **疾病早期預防與健康管理創新：AI 在個人化醫療中的角色(講題初擬)**	
課程摘要(暫)	本次演講探討健康風險預測在現代醫療保健中的作用，為學習者提供一個主動識別和管理疾病風險的框架，旨在賦能學員利用 AI 優化健康風險預測，實現疾病早期預防與健康管理創新。將深入探討預測模型的基礎——例如 Framingham 評分和 QRISK 評分——以及多模態數據（包括基因組學、生活方式因素和電子健康記錄）的整合，將預測結果轉化為臨床或公共衛生策略，提高預防效果與資源效率。
講師簡歷	**姓名**：**劉韻如** **現職**：臺北醫學大學人體研究處聯合人體生物資料庫主任/臺北醫學大學精準健康中心研究員 **簡歷**： 經歷 2019- 臺北醫學大學研究發展處人類微生物體核心實驗室主任 2024.6 臺北醫學大學人體研究處聯合人體生物資料庫主任

課程地點：4 樓誠樸廳

主題：健康風險預測	
課程： **阿茲海默症極早期血液生物標記檢測——IMR AD 於健康管理之應用**	
課程摘要	隨著台灣正式邁入超高齡社會，失智症的盛行率持續攀升，尤以阿茲海默症（Alzheimer's disease, AD）最為常見。阿茲海默症病程長、進展緩慢，臨床症狀出現時往往已進入中晚期，導致患者及家屬面臨巨大的照護負擔。因此，「極早期」的風險評估與病程預測成為當前失智症防治策略中的核心目標。 傳統診斷方式如正子斷層掃描（PET）或腦脊髓液（CSF）檢測雖具高準確性，但受限於侵入性高、檢查成本昂貴與取得不易等因素，難以作為常規篩檢工具。近年來，利用免疫磁減量技術（Immunomagnetic Reduction, IMR）於血液檢體中檢測 Aβ1-42、Tau 濃度，提供一種非侵入性、具高敏感度與可行性的極早期阿茲海默症風險評估方法。目前 IMR AD 檢測為全台唯一取得衛生福利部核准之體外診斷醫療器材（IVD）之阿茲海默症血液生物標記檢測項目，並已逐步導入健康檢查與預防醫學領域，協助中高齡族群進行大腦健康風險之早期識別與介入。 IMR AD 檢測可作為中年族群（建議年齡為 40-50 歲以上）定期健康評估的一部分，搭配常規項目如血糖與血脂檢測，共同關注「大腦健康」狀態。早期識別認知功能退化風險，可及時介入治療或生活型態改善，從而延緩病程進展，亦能大幅降低醫療與社會照護成本。
講師簡歷	**姓名**：**柯世祐** **現職**：衛生福利部雙和醫院 健康管理中心主任 **簡歷**： 學歷： 中山醫學大學醫學系 臺北醫學大學傷害防治學研究所 經歷： 新光醫院急診科臨床研究員 新光醫院急診科住院醫師

課程地點：2101 教室

主題：Navigation in modern dentistry 當代牙醫治療之導航應用	
課程： 我該使用動態導航嗎？以“標靶落點”來評估動態導航結果 Should I use dynamic navigation system？Evaluation the implant precision by “target zone” concept.	
課程摘要	Most of the studies on accuracy of implant placement had their results prone to bone-driven concept implantology. A new “target zone” concept is based on actual screw hole position upon planed, screw-type implant prosthesis. A model-based study shows that the use of dynamic navigation can improve the accuracy of implant placement, however, the benefit is different according to the tooth site and the experience of dentist. We believe this new target zone concept is closer to modern implantology and clinical situation in the field of accuracy of implant placement.
講師簡歷	**姓名**：**黃彥文** **現職**：1. Division of Periodontics, Department of Dentistry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 2. School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan **簡歷**： Visiting faculty member, Division of Periodontics, Department of Dentistry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan PhD student, School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.

課程地點：2101 教室

主題：Navigation in modern dentistry **當代牙醫治療之導航應用**	
課程： **根管導航，行不行？** **Guided Endodontic**	
課程摘要	Guided endodontics，指的是透過靜態導板或是動態導航的方式，來輔助手術和非手術性根管治療，也是近年來在牙髓病學領域發展熱絡的主題之一。面對錯綜複雜的根管系統，往往會讓人在治療中迷航，尤其是找尋細如髮絲的鈣化根管，更如大海撈針般困難重重。鈣化根管除了顯微鏡、超音波等等方式，隨著 CBCT 影像品質的提升，結合 3D 列印技術，利用導板來引導治療，在植牙領域已經不是新鮮事，那麼應用在要求更精準的根管治療呢？或是結合動態導航儀器，來引導找尋鈣化根管？靜態導板與動態導航之間，又有什麼各自的優勢跟限制呢？除了非手術性根管治療的應用，對於根尖手術，導板和導航，又能發揮什麼樣的優勢來輔助治療，本次演講將透過臨床案例來一一剖析。 The concept of "Guided Endodontics", including static guide and dynamic navigation, was introduced 9 years ago. Guided Endodontics is one of the most popular topic in endodontics in recent years. CBCT as a 3D anatomical map plays a critical role in guided endodontics. By combining CBCT images with 3D printing technology, static template can be customized and fabricated for special purposes such as guiding apical surgery, locating calcified root canals, or acting as a template for autotransplantation. On the other hand, dynamic navigation system can integrate instruments and CBCT images and give clinicians a real-time guide. These features could help to reduce the risk of unintentional iatrogenic damage to nearby anatomic structures and thus allowing the endodontist to perform minimally invasive treatment. This lecture will focus on the influence of guided endodontics accompanied by clinical cases and experience
講師簡歷	**姓名**：**林均霈** **現職**：國立台灣大學附設醫院牙髓病科兼任主治醫師 Adjunct Attending Dentist, Department of Endodontics, National Taiwan University Hospital **簡歷**： 林均霈 醫師 國立台灣大學醫學院附設醫院 牙髓病科 兼任主治醫師 林均霈醫師畢業於國立台灣大學牙醫學系，並獲得國立台灣大學臨床牙醫學研究所碩士學位，主修牙髓病學。其後，完成加拿大多倫多大學進階牙髓病學訓練，深化臨床與研究實務能力。林醫師現任國立台灣大學醫學院附設醫院牙髓病科兼任主治醫師，也在長木牙醫診所執業，也視微炬顯微教育中心床辦人，除了致力於臨床教學外，也致力於「動態導航技術於根管治療臨床應用」之相關研究與推廣。其研究成果屢次於國內外專業牙科學術會議中發表，並積極參與跨領域學術合作，深受業界肯定。 Dr. Chun-Pei Lin, DDS, MS Adjunct Attending Physician, Department of Endodontics

	National Taiwan University Hospital Dr. Chun-Pei Lin received her Doctor of Dental Surgery (DDS) and Master of Science (MS) in Clinical Dentistry, specializing in Endodontics, from National Taiwan University. She further completed an advanced endodontic training program at the University of Toronto. Dr. Lin currently serves as an adjunct attending dentist at the Department of Endodontics, National Taiwan University Hospital and practice in Longwood Dental clinic. She is also the founder of MicroTorch Microscope Training Center. Her research focuses on the clinical application of dynamic navigation systems in root canal therapy. She has participated in multidisciplinary collaborations and regularly presents her work at both national and international dental conferences.

課程地點：2101 教室

主題：Navigation in modern dentistry **當代牙醫治療之導航應用**	
課程： **導航是選擇還是信念？** **Is Navigation a Choice or a Philosophy?**	
課程摘要	Performing oral surgery with a dynamic navigation system is no longer a complicated task. Through sophisticated imaging technology and registration methods, navigation surgery can be accurate and fast. Currently, some individuals still find dynamic navigation challenging to use or have concerns about its accuracy. Today, we will use several cases to illustrate how dynamic navigation can enhance efficiency and accuracy. Perhaps the current setup and treatment costs are higher than those of traditional treatments, but this is a path of digital technology development, and we must all pursue this path.
講師簡歷	**姓名**：**林涵威** **現職**：Director of Leaderway OMS Dental Clinic, Taipei City, Taiwan Adjunct Visiting Staff of Oral and Maxillofacial Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan 立威口腔顎面外科牙醫診所 院長 亞東紀念醫院口腔顎面外科 兼任主治醫師 **簡歷**： DDS, School of Dentistry, Taipei Medical University (2007) MSc, Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University (2010) Oral and Maxillofacial Surgery Specialist (Diplomate 2014) Lecturer of All-on-4® and Navigation Co-founder of All-on-One Full Arch Rehabilitation Hands-on Course, Taiwan

課程地點：2102 教室

主題：Smart Nursing Valued Healthcare	
課程： **AI in Nursing 相關主題對智慧疾病照護成效**	
課程摘要	大數據和人工智慧（AI）在護理領域的應用正逐步改變傳統照護模式，特別是在智慧疾病照護方面展現出顯著成效。本次演講探討 AI 在智慧疾病照護中的應用現況、成效與挑戰，並展望未來發展方向。AI 能夠分析大量病患資料，協助護理人員早期識別病情變化，並提供個人化的照護建議，從而提高診斷準確性並減少醫療錯誤 。在實際應用中，AI 驅動的監測系統，如可穿戴裝置和即時警報平台，使護理人員能夠在病情惡化前察覺微小的生理變化，實現及時干預，降低併發症發生率，縮短住院天數，並降低再住院率 。然而，AI 在護理領域的整合也面臨挑戰，包括資料隱私風險、算法偏見以及對臨床判斷的過度依賴等倫理問題。因此，確保 AI 技術的使用，並在護理教育中強化相關能力，是未來發展的關鍵。
講師簡歷	**姓名**：**Erica Yu** **現職**：Professor and the Associate Dean & Department Chair for Undergraduate Studies at Cizik School of Nursing at UTHealth Houston, USA **簡歷**： Yu served as a national/international practice, education, and accreditation consultant for colleges of nursing in the United Staes and Taiwan. Dr. Yu has focused her career on curriculum development, leadership, student/faculty mentorship, and undergraduate nursing education. She has consulted and collaborated as an academic partner with Texas Medical Center hospitals in their development of nurse residency programs for transitioning new nurses from academia to practice. She is a member of the AACN Vizient Nurse Residency National Strategic Planning Committee and serves nationally as a Commission on Collegiate Nursing Education (CCNE) on-site evaluator for accreditation. Education The University of Texas at Austin, School of Nursing, Austin, Texas PhD August 2006 University of Nebraska Medical Center, College of Nursing, Omaha, NE MSN May 1997 Kaohsiung Medical University, College of Nursing, Kaohsiung, Taiwan BSN May 1992

課程地點：2102 教室

主題：Smart Nursing Valued Healthcare

課程： 醫院的智慧照護	
課程摘要	隨著科技的快速進步，智慧醫療已成為現代醫院提升照護品質與效率的關鍵。本次演講將探討醫院如何運用人工智慧（AI）、物聯網（IoT）與大數據等技術，實現智慧照護，提升病患安全與滿意度。內容涵蓋智慧醫療的發展趨勢與應用，包括智慧病房、遠距監測、預測分析等。學員將了解如何透過 AI 技術進行病情預測與風險評估，並運用 IoT 設備進行即時監控，實現個人化與精準的照護服務。此外，課程亦探討智慧醫療在提升醫療效率、減少醫療錯誤、降低成本等方面的成效。透過實際案例分析深入了解智慧醫療在臨床實踐中的應用，並探討其在醫療體系中的整合與挑戰。
講師簡歷	**姓名**：**朱冠郁** **現職**：台北醫學大學附設醫院護理部督導長 **簡歷**： 民國 79 年畢業-護理助產科(高職)

課程地點：2102 教室

主題：Smart Nursing Valued Healthcare	
課程： **重塑護理: 以價值為本的護理臨床與教育革新**	
課程摘要	在現代醫療環境中，護理專業正面臨從技術導向轉向以病人為中心的價值導向轉變。本次演講將探討如何將人文關懷、倫理素養與終身學習等核心價值，融入護理臨床實踐與教育體系，從而提升照護品質與護理人員的專業滿意度。 內容涵蓋護理教育的發展與創新，強調護理人員需具備良好的溝通技巧，並建立治療性人際關係，以提升病人的照護品質 ，特別關注人文教育在護理專業中的價值，指出護理人員在病人照護過程中，必須具備人文素養，才能看到病人的身影，反思與實踐人性的關懷，這是病人身心療癒的基礎，也是護理專業的核心價值 。
講師簡歷	**姓名**：**蔡佩珊** **現職**：台北醫學大學醫護理學院教授兼院長 **簡歷**： 學歷 2001 佛羅里達大學護理學博士 1991 佛羅里達大學護理學碩士 1986 臺北醫學院護理系學士 經歷 2023- 臺北醫學大學護理學院院長 2021-2024 馬來亞大學教師升等及新聘審查委員 2021-2022 衛生福利部附屬醫療及社會福利機構管理會委員 2021-2021 國家衛生研究院論壇-後疫情時代慢性病防治問題與對策委員 2021-2022 Member, Global Advisory Committee, Quacquarelli Symonds (QS) 2020-2024 Editor, Editorial Board, Biological Research for Nursing 2020-2024 Editor, Editorial Board, Journal of Nursing Research 2020.04-2020.06 臺北醫學大學國際研究組暫代組長 2019-2023 國際護理榮譽學會中華民國分會監事 2017-2020 Member, International Academic Advisory Committee, QS Asia-Pacific Professional Leaders in Education (QS APPLE) 2017-2019 國際護理榮譽學會中華民國分會常務監事 2016-2023 臺北醫學大學國際事務處國際長 2015- 臺北醫學大學護理學系教授 2015-2018 臺北醫學大學榮譽教授 2013-2017 衛生福利部護理及健康照護司護理諮詢會委員 2013-2017 國際護理榮譽學會中華民國分會理事長 2013-2016 臺灣護理教育學會理事會理事 2013-2016 中華民國護理師護士公會全國聯合會國際委員會委員 2012-2017 臺北醫學大學護理學院副院長

	2011-2024 臺灣護理學會編輯委員會委員 2010-2016 臺灣護理教育學會文書編輯委員會委員 2008-2015 臺北醫學大學護理學研究所教授 2006 美國華盛頓大學護理學院訪問學者 2005- 臺北市立萬芳醫院護理部副主任 2005-2008 臺北醫學大學護理學研究所副教授 2003-2005 臺北醫學大學護理學研究所助理教授 2002-2003 臺北醫學大學護理學研究所兼任助理教授 2001-2002 佛羅里達大學研究型助理教授 研究興趣 心理生理學 慢性疼痛 生物回饋應用 壓力管理 生物行為研究 睡眠

課程地點：2103 教室

主題：NGS in infection disease	
課程： **Clinical Metagenomics Next-Generation Sequencing (mNGS) for Infectious Diseases Diagnosis**	
課程摘要	This course will utilize case analyses, data interpretation, and practical operations to help participants gain an in-depth understanding of mNGS applications in clinical infectious disease diagnosis and explore its future development directions. In this course, I will introduce the application of clinical metagenomic next-generation sequencing (mNGS) in diagnosing infectious diseases, particularly its potential in severe infections such as sepsis, pneumonia, and meningitis. Traditional microbial culture methods, while standard diagnostic tools, often face challenges in clinical settings, including culture-negative results, prolonged waiting times, and the inability to identify rare pathogens. mNGS technology, through high-throughput sequencing, enables comprehensive detection of microbial DNA in samples like blood and cerebrospinal fluid within a short time, which is crucial for rapid pathogen identification, guiding antibiotic use, and reducing the risk of antimicrobial resistance. However, the clinical application of mNGS still faces several challenges, including the complexity of data analysis, control of false-positive rates, cost, and reporting time. Therefore, establishing standardized operational procedures, a comprehensive quality control system, and integrating clinical symptoms and imaging results are key to realizing its clinical value.
講師簡歷	**姓名**：**王復德** **現職**：部定教授/臺北醫學大學附設醫院成人感染科主治醫師/台灣感染管制學會理事長 **簡歷**： 學歷： 高雄醫學院醫學系 經歷： 臺北榮民總醫院內科部感染科主任 臺北榮民總醫院感染管制室主任

課程地點：2103 教室

主題：NGS in infection disease	
課程： **次世代定序在血流感染的應用** **Application of Next-Generation Sequencing in Bloodstream Infections**	
課程摘要	Bloodstream infections represent a significant cause of morbidity and mortality worldwide, with diagnosis critically dependent on traditional blood cultures. However, these methods suffer from major limitations, including prolonged turnaround times and low sensitivity, particularly in cases involving prior antibiotic use or fastidious pathogens. This diagnostic delay often necessitates the use of broad-spectrum antibiotics, contributing to the rise of antimicrobial resistance. Next-Generation Sequencing (NGS), particularly through a metagenomic approach, offers a transformative, culture-independent solution. In the talk I will review clinical examples demonstrating the utility of NGS in resolving complex scenarios. While challenges related to cost, workflow optimization, and data interpretation remain, NGS is poised to revolutionize BSI diagnostics. Its continued integration into clinical practice promises to enhance diagnostic accuracy, improve patient outcomes.
講師簡歷	**姓名**：**劉伯瑜** **現職**：台中榮總感染科醫師 Infectious Diseases Physician, Taichung Veterans General Hospital, Taiwan(Liu et al. 2024) **簡歷**： Dr. Po-Yu Liu, Chief of the Division of Infectious Diseases at Taichung Veterans General Hospital, Taiwan, and Associate Professor at National Chung Hsing University, is renowned for translating genomic technologies into bedside solutions against infectious diseases. Board-certified in internal medicine, emergency medicine, and infectious diseases, he earned his MD from Chung Shan Medical University (1999) and a PhD in molecular epidemiology from National Chung Hsing University (2013), complemented by a visiting-scholar stint at Lawrence Berkeley National Laboratory. Liu’s research couples Oxford Nanopore sequencing with clinical studies to reveal within-host evolution of clinically important pathogens, underpinning rapid diagnostics that shorten time-to-therapy for sepsis.

課程地點：2104 教室

主題：分散型藥品臨床試驗(DCT)之執行實務與倫理考量	
課程： **分散型臨床試驗之執行實務**	
課程摘要	1. 因應科技技術進步新常態發展，針對 112 年 6 月 12 日 FDA 藥字 1121406000 號衛生福利部公告「藥品臨床試驗執行分散式措施指引」作為分散式措施作業參考，提醒各臨床試驗應依據該指引落實評估及執行。 2. DCT 所使用的數位工具之應用與發展潛力。 3. 為確保執行分散式措施之風險效益評估合宜，針對藥品臨床試驗如有採用分散式措施，本會比照衛福部要求，研究人員申請 IRB 時，請一併檢附藥品臨床試驗分散式措施檢核表審查。
講師簡歷	**姓名**：**汪志雄** **現職**：國泰醫院人體試驗審查委員會主委 **簡歷**： 國泰綜合醫院麻醉科主任(2009/11~迄今) 國泰綜合醫院教學部主任(2022~2024) 國泰綜合醫院人體試驗倫理委員會主任委員(2018~迄今) 國防醫學院醫學科學研究所所長(2008~2009) 國防醫學院醫學系主任(2006~2009) 三軍總醫院教學副院長(2006~2009) 三軍總醫院麻醉部主任(2000~2006) 國防醫學院麻醉學科教授兼主任(2000~2006) 三軍總醫院人體試驗倫理委員會主任委員(2000~2009)

課程地點：2104 教室

主題：分散型藥品臨床試驗(DCT)之執行實務與倫理考量	
課程： **分散型臨床試驗之倫理考量**	
課程摘要	臨床試驗經常面臨研究結果之可推論性(generalizability)及招募對象代表性不足之疑慮，研究方法須針對此問題進行調整方能持續精進。2020 年起歷時 3 年多的新冠肺炎全球大流行，也顯露出臨床試驗以醫學中心為基礎而執行之中心化模式恐有所不足。發展「真實世界數據」分析及「分散式臨床試驗」等概念於是受到更多重視與發展。本文指出傳統臨床試驗有所不足之處、介紹真實世界數據研究及分散式臨床試驗之內涵與特色、執行分散式臨床試驗涉及之研究倫理考量，並提出相關實務建議。
講師簡歷	**姓名**：**何橈通** **現職**：財團法人醫學研究倫理基金會董事長 **簡歷**： 臺北榮民總醫院主治醫師/陽明大學特約教授級榮譽教授 臺北榮民總醫院教學研究部主任 臺北榮民總醫院內科部新陳代謝科主治醫師 臺北榮民總醫院內科部新陳代謝科主任 陽明大學醫學院院長